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Letter from the Commission
The Governor’s Commission on Alcohol and Drug Abuse Prevention, Intervention and Treatment (hereafter
referred to as “the Commission”) was established by the state legislature in 2000, with its membership and duties
articulated in RSA 12-J:4. These duties include the following:
-

Developing and revising as necessary a statewide plan for the effective prevention of alcohol and drug
abuse, particularly among youth; and a comprehensive system of intervention and treatment for individuals
and families affected by alcohol and drug abuse;

-

In partnership with the NH Department of Health and Human Services, overseeing disbursement of the
Alcohol Abuse Prevention and Treatment Fund;

-

Promoting collaboration between and among state government agencies and communities to foster the
development of effective community-based alcohol and drug abuse prevention and treatment programs;

-

Promoting the development of treatment services to meet the needs of citizens addicted to alcohol or other
drugs; and

-

Identifying unmet needs and identifying the resources required to reduce the incidence of alcohol and drug
abuse in NH and to make recommendations to the Governor regarding legislation and funding to address
such needs.

In its ongoing surveillance of substance use issues in the state, the Commission has noted the epidemic of
prescription drug abuse as a public health crisis in New Hampshire, with an alarming increase in prescription drug
related deaths now outpacing traffic fatalities in the state. Crimes related to prescription drug abuse are also on the
rise, including theft and illegal distribution. Such abuse has both economic and social costs that are a burden to
local communities and the state as a whole.
Over the past year the Commission has led an effort to respond to the crisis through the development of this
comprehensive strategy document. This effort dovetails with similar work on the federal level, which was
articulated by the Office of National Drug Control Policy (ONDCP) in its report, Epidemic: Responding to
America’s Prescription Drug Abuse Crisis. Gil Kerlikowske, Director of ONDCP, joined the Commission in
October to review and comment on recommendations proposed in the New Hampshire Call to Action, along with
stakeholders from law enforcement, health care, education, local and state government and business.
The Commission thanks the many stakeholders – both local and national – who participated in focus groups,
convenings, and other efforts to gather data and develop this strategy document. Particular thanks goes to the New
Hampshire Center for Excellence in Substance Abuse Prevention and Treatment, a co-funded initiative of the
New Hampshire Bureau of Drug and Alcohol Services, the Commission and the New Hampshire Charitable
Foundation, for their leadership in facilitating the strategy development process and producing this document for
dissemination to the public.
The Commission looks forward to working with these stakeholders, the Legislature and the Governor’s Office to
ensure effective implementation of the recommendations contained herein. We are fortunate as a state to have
seen local communities and others already begin implementation of a number of initiatives and policy efforts that
we recommend here, but there remains much work to do to ensure we can turn the tide of this epidemic and
reduce the negative economic and social impact prescription drug misuse and abuse has on our state.
We hope you will join us in responding to this Call to Action.

Timothy R. Rourke, Chairman
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Executive Summary
New Hampshire’s awareness of and response to the threat of prescription drug abuse began
as early as 2004, when prescription drug-related deaths were on the rise and state agencies
began to make policy changes in response to the emerging threat. In spite of these important
strides, increased marketing and accessibility of prescription drugs, low perceptions of the
risks associated with the misuse and abuse of prescription drugs, and a rise in prescription
drug fraud have overtaken these early and isolated efforts.
According to the most recent data available, the number of deaths in New Hampshire
attributable to drug-related deaths – the majority of which are prescription drug-related – has
outnumbered traffic related fatalities in four out of the last five years, and the New
Hampshire rate of young adults reporting nonmedical use of pain relievers in the past year is
second highest among the states and territories.
These alarming statistics prompted the Governor’s Commission on Alcohol and Drug Abuse
Prevention, Intervention and Treatment to lead a year-long effort to mine federal, national,
state and local recommendations in order to develop a comprehensive action plan to respond
to the threat in a more timely and comprehensive manner.
The assessment and planning work of the Commission and its task forces during 2011 led to
key recommendations, including the following:
-

Increase professional development and training within and across multiple sectors

-

Improve prescribing, dispensing, storage, disposal and enforcement practices and
policies

-

Increase surveillance and monitoring at the individual (patient) and system level
(population data)

-

Increase public education and awareness (including patient education)

The Commission has engaged state agencies and regulatory authorities to support community
stakeholders within health, safety, education, business and government sectors to consider
and carry out the recommendations within this Call to Action. In so doing, the Commission
seeks to reduce drug-related deaths and nonmedical use of pain relievers by 15% over the
next five years to protect the safety and health of our citizens from the threat of prescription
drug abuse.
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Introduction
The misuse and abuse of prescription drugs has become a leading cause of harm among New
Hampshire adults, resulting in more deaths each year than those caused by car crashes. The rise of
prescription drug abuse is rooted in multiple contributing factors, including increasing availability
and accessibility, a misperception of low risk of harm relative to other illicitly obtained drugs,
direct to consumer marketing of prescription medications, and a lack of education about the
potential risks of misusing or abusing prescription drugs, including the risk of addiction and death.
Prescription medications include a wide range of abusable drugs, including opioids (for pain),
central nervous system depressants (for anxiety and sleep disorders), and stimulants (for attention
deficit disorder and narcolepsy).
CLASSES OF COMMONLY ABUSED PRESCRIPTION MEDICATIONS

OPIOIDS

Benzodiazepines:
diazepam / Valium®
alprazolam / Xanax®
triazolam/Halcion®
estazolam/ProSom®
clonazepam/Klonopin®

Barbituates:
pentobarbital sodium/
Nembutal®
mephobarbital/Mebaral®
phenobarbital /Luminal
Sodium®

STIMULANTS

dextroamphetamine / Dexedrine®
methylphenidate / Ritalin® & Concerta®
amphetamines / Adderall®

The most potent and addictive medications being prescribed are opioid pain relievers such as
oxycodone. Opioids play a critical role in the quality of life for those with acute and/or chronic
pain; however, it is imperative that prescribers and patients alike are aware of their potential harm.
According to the National Institute on Drug Abuse (NIDA) at the National Institutes of Health,
opioids used in the treatment of pain pose several risks1:
ADDICTION Prescription opioids act on the same receptors as heroin and therefore can be

highly addictive. People who abuse them sometimes alter the route of administration (e.g.,
snorting or injecting vs. taking orally) to intensify the effect; some even report moving
from prescription opioids to heroin.
OVERDOSE Opioid abuse, alone or in combination with alcohol or other drugs, can depress

respiration and lead to death. Overdose is a major concern, as the number of fatal
poisonings involving prescription pain relievers has more than tripled since 1999.
HEIGHTENED HIV RISK Injecting opioids increases the risk of HIV and other infectious

diseases through use of unsterile or shared equipment.

1
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hydrocodone / Vicodin®
oxycodone / OxyContin®
propoxyphene / Darvon®
hydromorphone / Dilaudid®
meperidine / Demerol®
diphenoxylate / Lomotil®

CENTRAL NERVOUS SYSTEM DEPRESSANTS
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NIDA also has articulated the risks associated with the misuse or abuse of other prescription
central nervous system (CNS) depressants used to treat anxiety and sleep disorders:
ADDICTION & DANGEROUS WITHDRAWAL SYMPTOMS CNS depressants are addictive

and, in chronic users or abusers, discontinuing them without a physician's guidance can
bring about severe withdrawal symptoms, including life-threatening seizures.
OVERDOSE High doses of CNS depressants can cause severe respiratory depression. This

risk increases when CNS depressants are combined with other medications or alcohol.
Stimulants used to treat attention deficit disorder and narcolepsy also pose risks including
addiction, seizures, psychosis and cardiovascular complications.

Introduction

Although swift and comprehensive action is necessary to prevent and reduce prescription drug
misuse and abuse, it is imperative that critical pain treatment and medication management remain
accessible to those for whom these medications are therapeutic and life-saving.

2
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A Nation’s Epidemic
National data show the quantity of medications made available through valid prescriptions steadily
increasing since the 1990’s, increasing overall accessibility and the potential for misuse and abuse.
According to the White House Office of National Drug Control Policy, the milligram-per-person
use of prescription opioids per year in the U.S. increased from 74 milligrams to 369 milligrams
between 1997 and 2007, an increase of 399% in ten years,2 and pharmacies dispensed 83 million
more opioid prescriptions in 2009 compared to 2000, an increase of 48%.3 According to a 2008
study by the International Narcotics Control Board, the United States consumes 99 percent of the
world's hydrocodone and 83 percent of its oxycodone.4
Trends in the percentage of persons using
prescription drugs (1999-2008)
* Significant linear trend from 1999-2000 through 2007-2008

Rate of prescription painkiller sales, death and
substance abuse treatment admissions (1999-2010)
Sales

The annual milligramper-person use of prescription
opioids in the U.S. increased
from 1997 to 2007.

Deaths
Treatment

Source: White House Office of
National Drug Control Policy
Sources: National Vital Statistics System, 19992008; Automation of Reports and Consolidated
Orders System (ARCOS) of the Drug Enforcement
Administration (DEA), 1999-2010; Treatment
Episode Data Set, 1999-2009
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A Nation’s Epidemic

Source: CDC/NCHS, National Health and Nutrition Examination Survey
Note: Age adjusted by direct method to the year 2000 projected U.S. population

Increases in availability and
accessibility have also led to
drug-seeking crimes, referred to
as “diversion”, which include but
are not limited to forged
prescriptions, theft, and doctor
shopping – the practice of
contacting multiple doctors for
the purpose of acquiring
prescription medications for
abuse or illicit resale. As
prescribing has increased, there
have been similar increases in the
prevalence of fatal prescription
overdoses and in the prevalence
of treatment admissions for
prescription painkiller abuse and
dependence.
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In response to the growing problem nationally, the Executive Office of the
President of the United States issued a briefing in April 2011 titled, Epidemic:
Responding to America’s Prescription Drug Abuse Crisis, which encourages
states to develop an effective response to “the Nation’s fastest-growing drug
problem”. The briefing characterized prescription drug misuse as an epidemic
based on the following indicators:
One in three people aged 12 and over who used
drugs for the first time in 2009 began with the
use of a prescription drug for nonmedical purposes;5
In 2008-2009, over 70% of those who abused pain
relievers reported getting them from friends or
relatives while 5% obtained them from a drug
dealer or the internet;6
Prescription drugs are second only to marijuana
as the most prevalent drug of abuse;7

Opiates represent

¾ of all
prescription drugs
being abused.
Source: Epidemic: Responding to
America’s Prescription Drug Abuse Crisis

A Nation’s Epidemic

Illicit drug abuse, particularly prescription drug abuse, among the military increased
from 5% to 12% between 2005 and 2008;8
In 2009, retail pharmacies dispensed 48% more prescriptions for opioid pain relievers
than in 2000;9
Opiate overdoses are increasing due to abuse of prescription pain relievers;10
Overall, opiates represent three-fourths of all prescription drugs being abused.11
Source Where Pain Relievers Were Obtained for Most Recent
Nonmedical Use Among Past Year Users Aged 12 or Older: 2010

Source: NSDUH 200612
4
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New Hampshire’s Epidemic
The most telling indicator of New Hampshire epidemic is the steady increase in total drug-related
deaths since 2000, with the majority of the increase attributable to prescription drug overdose.
The number of drug-related overdose deaths in the state increased substantially between 2002 and
2010, more than doubling from 80 deaths to 174 over the eight year period. Prescription opioids
are the most prevalent drug of abuse leading to death.13
With such a devastating toll already evident in the state, the Commission
initiated a community- and state-level assessment of the scope and severity of
the threat, of current efforts to address the negative impacts affecting many
aspects of public safety and health, and of opportunities for community- and
state-level response and action. This assessment process, undertaken by the
Commission and its prevention task force, is described below and is the
genesis of this publication.

MAR

A survey of
8 state agencies
represented on the
Commission

16 key informant
interviews with licensing
boards and state agency leaders

A Strategy Summit held October 3, 2011
engaging over 160 state & community
stakeholders & lawmakers in the
review and prioritization of strategies
derived from federal, national, state &
local sources

APR

MAY JUN JUL AUG SEP

OCT

2011 – Governor’s Commission on Alcohol and Drug Abuse
Past year nonmedical use of pain
relievers by age groups in NH

In addition to information derived
through stakeholder engagement,
quantitative data accessed by the
Commission includes state-level data
from the Youth Risk Behavior Survey,
the National Survey on Drug Use and
Health, the Client Event Data Set of statefunded treatment providers, Mental
Health Intake Screening data of state
corrections populations, and cause of
death statistics from the New Hampshire
Medical Examiner’s Office. A summary
of key findings from these data sources is
provided as context for the Commission’s
Call to Action.

Source: 2008-2009 NSDUH
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New Hampshire’s Epidemic

A community survey of over
110 stakeholders and
community leaders,
including representatives
from the law enforcement,
education, social service,
health & medical sectors
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According to the 2008-2009 National Survey on Drug Use and Health, New Hampshire’s young
adults are abusing pain medication at a significantly higher rate than young adults nationwide
(NH =16.78% vs. US=11.94%); New Hampshire’s rate of nonmedical use of pain relievers by 18
to 25 year olds is the second highest among the states and territories.

New Hampshire’s Epidemic

Between 2008 and 2010, the percentage of individuals entering state-funded substance abuse
treatment for oxycodone increased by over 60%, from 11.6% of patients in 2008 to 18.7% of
patients in 2010, while admissions for alcohol, cocaine, marijuana, and heroin either decreased or
stayed the same. In 2010, oxycodone also became the second most prevalent drug of abuse after
alcohol among those entering state-funded substance abuse treatment.15
According to the New Hampshire
Medical Examiner’s Office the number
of New Hampshire deaths resulting
from oxycodone has more than tripled
since 2000. The total number of drugrelated deaths rose to 174 in 2010.
Almost 20% of these deaths (34) were
determined to be suicides caused by
intentional drug overdose.16

Number of Drug Related Deaths in NH

Source: Dr. Thomas Andrew, NH Medical Examiner’s Office

In 2010 methadone and oxycodone became the first and second leading agents in the cause of
drug-related deaths in New Hampshire.17
Approximately one in five (20.4%) New Hampshire high school students reported having taken a
prescription drug without a doctor’s prescription at least once in their lifetime, while one in ten
(10.4%) reported having taken a prescription drug without a doctor’s prescription at least once in
the past 30 days.18
A 2005 national study of 7th through 12th graders found that 40% believed using prescription
drugs was safer than using illegal drugs, 29% thought that pain relievers were not addictive, and
62% of teens who reported abusing prescription pain relievers said they do so because they are
easily accessible through parents’ medicine cabinets.19
In 2010 sixteen percent of substance abusing adults entering state correctional facilities reported
prescription drugs as their drug of first preference.20
From April of 2010 to April of 2011, the Drug Diversion Unit of the NH Department of Safety
initiated 32 investigations resulting in one search warrant, four consent searches, and 50 arrests
related to prescription drug abuse.21

6
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State Priorities
In this Call to Action, the Commission supports the federal recommendation22 that the following
long-term impacts be achieved within five years:

A reduction in the percentage of individuals 12 and older who report
non-medical use of pain relievers in the past year by 15%
A reduction in the number of drug-related overdose deaths by 15%
To realize these goals, this Call to Action frames the issue in two parts:
Part I: Recommendations for Action
Recommended strategies by key stakeholder domains

Part II: Commitments to Action
Specific commitments to action by state level agencies and stakeholder groups

This two-tiered plan will ensure a wide range of opportunities for and commitments to actionable
strategies that comprise the state’s comprehensive response to the growing epidemic of
prescription drug abuse. Strategies included in this document were prioritized as highly or
moderately feasible with a high to moderate impact by stakeholders at the 2011 Prescription Drug
Abuse Prevention Strategy Summit and/or in review by the task forces of the Governor’s
Commission. They are organized within the following domains:

Recommended strategies in the first
section of this document are organized
by the following domains:

PROFESSIONAL DEVELOPMENT & TRAINING
PUBLIC EDUCATION & AWARENESS
PRESCRIBING & DISPENSING

STORAGE & DISPOSAL
SURVEILLANCE & MONITORING
RESOURCE DEVELOPMENT

7
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Recommendations for Action
Recommended strategies within this plan have broad implications from the practitioner at the
community level to legislative policy at the government level and across key state and community
sectors.
This cross-section of stakeholders and strategy domains is designed to harness the resources and
opportunities that exist within the state and local communities to effect positive change in service
to the state’s goal of preventing and reducing prescription drug abuse.
Recommendations and opportunities for action are presented by key stakeholder sectors that exist
within communities and state-level leadership. For each key sector, recommendations are
provided that have been derived from a cross-section of national,23,24 state25 and local26 sources.
These sectors are the health and medical field, safety and law enforcement, education, business,
and government.

 Prescribers
 Dispensers

 Health Educators
 Addiction Treatment

SAFETY & LAW ENFORCEMENT











Emergency Care
Behavioral Health
Surgeons
Injury Prevention

Primary Care
Institutional Care
Pain Clinics
Suicide Prevention

 Drug Diversion Investigators
 Police Standards & Training

 Local Law Enforcement
 Emergency Medical Technicians & First Responders

EDUCATION
 Public & Private Schools
 Campus Health Services

 School Nurses
 Campus Police

BUSINESS
 Business Owners & Operators
 Human Resource Departments






Student Assistance Counselors
College Counseling Departments
Staff & Administration
Guidance Counselors & Social Workers

 Employee Assistance Programs
 Risk Management

 Senior Management
 Health Educators
 Safety Compliance Officers

GOVERNMENT
 Federal Government
 State Lawmakers

 County Officials
 Local Governing Boards
 State Agencies & Commissions
11
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HEALTH & MEDICAL

Recommendations for Action

HEALTH & MEDICAL
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Health & Medical Recommendations Overview
PROFESSIONAL DEVELOPMENT & TRAINING
1:1 Increase training availability and access for the health care workforce
1:2

Increase opportunities for cross-training between prescribers, dispensers, health educators,
and law enforcement specializing in drug diversion

1:3

Increase training opportunities for addiction prevention and treatment professionals in
evidence-based treatment and after-care relative to prescription drug abuse

1:5

Increase professional collaboration between providers of primary care, behavioral health,
addiction treatment, substance abuse prevention, and alternative therapies

PUBLIC EDUCATION & AWARENESS
1:6

Provide education to all patients and clients regarding the risks and warning signs of
prescription drug abuse and misuse, proper storage and disposal of medications, and
identify resources available for addiction treatment or recovery services

PRESCRIBING & DISPENSING
1:7

Prescribers should check a patient’s prescription history before prescribing controlled
substances

1:8

Prescribers should screen for substance abuse as part of standard clinical examination and
assessment

1:9

Prescribers should provide medication guides and counseling to patients relative to
potential harm, including addiction

1:10

Prescribers should closely evaluate, monitor and even test patients for prescription drug
misuse and abuse

STORAGE & DISPOSAL
1:11

Patient education should include information about proper storage and disposal of unused
medications

1:12

Health and medical staff and facilities should promote and support local “Take-Back”
events to encourage safe and regular disposal of unused medications

1:13 Pharmacies may consider serving as medication disposal sites
15

Health & Medical Recommendations Overview

1:4 Increase educational requirements for those seeking to enter the health and medical field
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Health & Medical Recommendations Overview

SURVEILLANCE & MONITORING
1:14

Prescription drug monitoring should be instituted by means of a centralized database
accessible to prescribers and dispensers

1:15

Prescribers and prescribing facilities may consider patient contracts and other protocols to
monitor and detect prescription drug diversion and/or abuse

1:16

Dispensers should take increased precautions to protect stock and prevent unlawful access
to prescription drugs

1:17

Licensing boards and authorities should monitor, investigate and enforce policies and
encourage enhanced protocols to deter abuse and diversion

1:18

Referral to appropriate intervention or treatment should be provided if indications of abuse
or dependence exist

16
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Health & Medical Recommendations

Prescribers - Dispensers - Health Educators - Addiction Treatment

Health and medical professionals also have unique opportunities to talk with patients about the
danger of prescription drug abuse and addiction, to discuss ways to safeguard medications to
prevent access by others, and to identify patients who may be abusing medications to refer them to
treatment.
The Call to Action in the health and medical sector seeks to engage the broadest spectrum of
professionals and practitioners in strategies to prevent and reduce prescription drug misuse and
abuse in New Hampshire. The health and medical sector includes all members of the health care
workforce and their employers, including but not limited to those indicated below.
PRESCRIBERS

DISPENSERS

HEALTH EDUCATORS

ADDICTION TREATMENT

Primary care practitioners,
emergency room staff,
surgeons, dentists & oral
surgeons, pain care
professionals, psychiatrists,
nurse practitioners, and other
medical professionals licensed
to prescribe

Pharmacists, pain clinics,
institutions such as nursing
homes & correctional facilities
licensed to dispense
prescribed medication

Health educators in schools,
communities, housing
authorities, social service
organizations, and
institutional settings; injury
prevention, suicide
prevention, and poison control
professionals

Licensed alcohol & drug
counselors, therapeutic
counselors, social workers,
and recovery support workers

During this plan’s development it was noted that individuals abusing pain medication may resort
to extreme measures to gain access to medications that further complicate and challenge the
practice of prescribing medication. For example, it was reported that there have been cases of
drug seekers presenting in New Hampshire emergency rooms for dental pain that emergency room
17

Health & Medical Recommendations

The health and medical sector within the state plays a unique and critical role in efforts to address
the threat of prescription drug misuse and abuse in that they are one source of the medications that
hold the potential for abuse. Prescribing physicians, surgeons, emergency room staff and other
medical, dental and mental health professionals are in a difficult, front-line position of having a
responsibility to treat chronic and acute conditions requiring pain and symptom relief within a
changing landscape wherein patients may be seeking the drugs specifically for abuse or diversion
for illicit activity.

Call to Action: Responding to New Hampshire’s Prescription Drug Epidemic

January 2012

staff may not be able to adequately assess, thereby potentially increasing the likelihood pain
medication will be prescribed. Drug seekers may also leave dental or other medical problems
untreated in order to maintain the condition that requires pain medication or the appearance of
requiring pain medication. These and other conditions and situations are exploited by drug seekers
to thwart a prescriber’s reliance on objective means to determine the cause and severity of pain.

Health & Medical Recommendations

Interviews conducted in the development of this plan also revealed that many individuals who
become drug seekers fall into their abuse and dependence as a result of a valid health or medical
condition requiring pain or other symptom relief and that the health and medical field must give
equal attention to treating symptoms and conditions as to preventing complications from such
treatment, including the potential of abuse and addiction.
New Hampshire’s health and medical field has already taken the lead in revising pain treatment
guidelines and improving patient monitoring to deter prescription drug abuse. To assist
stakeholders in responding to the Call to Action, resources and examples in support of
recommended strategies are provided. These and other local efforts that have shown success are
highlighted along with state and national resources, including websites, guidelines, and materials.
Links to these resources are provided at the end of the Health & Medical section.

PROFESSIONAL DEVELOPMENT & TRAINING
1:1 Increase training availability and access for the health care workforce
All health care professionals licensed to prescribe medication should receive comprehensive
training in the following areas to increase awareness of prescription drug misuse and abuse, to
implement effective prevention approaches, and to intervene early if a problem arises.
PRESCRIBERS
Evaluation & treatment of pain
Effective pain management
Reviewing patient history
Patient monitoring & contracts
Abuse prevention
Physiology of addiction
Problem identification & referral
Screening for abuse &
dependence

DISPENSERS
Warning signs of abuse &
dependence
Internal drug diversion
Monitoring of customer
prescription drug fills &
patterns
External drug diversion

HEALTH EDUCATORS
Safe storage & disposal of
medication
Warning signs of abuse &
dependence
Abuse prevention
Problem identification &
referral

ADDICTION TREATMENT
Evidence-based treatment for
opioid addiction
Medication-assisted recovery
Long-term recovery planning &
support services

Recommended training topics include but are
not limited to those indicated above.
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Federal legislation has been submitted recently to require a minimum training course for anyone
licensed to prescribed medication. The legislation, the Ryan Creedon Act of 2011, H.R. 2119, was
filed on June 3, 2011, by leaders of the Congressional Caucus on Prescription Drug Abuse and
named after a constituent of U.S. Representative Mary Bono Mack who died from a prescription
drug overdose.
This legislation seeks to amend the Controlled Substances Act to require practitioners to:
Obtain particular training or special certification, approved by the Attorney
General, on addiction to and abuse of controlled substances and appropriate and
safe use of controlled substances in schedule II, III, IV, or V, and for other
purposes.27

The draft “Blueprint for Prescriber Continuing Education Program” is available at:
http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf
This FDA requirement and resulting resources will play an important role in the accessibility of
targeted professional development and training for prescribers and dispensers.

PROFESSIONAL DEVELOPMENT & TRAINING
1:2

Increase opportunities for cross-training between prescribers, dispensers,
health educators, and law enforcement specializing in drug diversion

Cross-training opportunities that bring diverse disciplines together are advantageous to creating
opportunities for collaborative and coordinated strategies to prevent prescription drug abuse and
diversion. For example, the New Hampshire Board of Pharmacy is encouraging collaborative
trainings and information-sharing between prescribers and dispensers to share ideas for more
coordinated abuse prevention. Cross-training opportunities may also exist between medical and
pharmacy schools such as Dartmouth College and the Massachusetts College of Pharmacy in
Manchester, New Hampshire.
Additionally, in response to the growing prescription drug abuse problem in New Hampshire, the
Department of Safety’s Drug Diversion Unit was established to investigate various crimes
involving diversion of pharmaceutical drugs, including prescription fraud, doctor shopping, illegal
prescribing by medical professionals and employee thefts at pharmacies. In addition to this
charge, the Drug Diversion Unit commits half of its staff time to provide free trainings both within
law enforcement and other disciplines to prevent unlawful diversion of prescription medications.
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Additionally, in November 2011, the U.S. Food and Drug Administration (FDA) requested public
comment on new risk evaluation and mitigation strategies (REMS) to be required of the sponsors
of long-acting and extended-release (LA/ER) opioid drugs. The central component of the Opioid
REMS is an education program for prescribers (e.g., physicians, nurse practitioners, physician
assistants) so that LA/ER opioid drugs can be prescribed and used safely. The FDA announced
that it expects drug sponsors to provide prescriber training conducted by accredited continuing
education providers without cost to health care professionals.
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PROFESSIONAL DEVELOPMENT & TRAINING
Increase training opportunities for addiction prevention and treatment
1:3 professionals in evidence-based practices and after-care relative to
prescription drug abuse

Health & Medical Recommendations

There are several state and regional training centers to support professionals in addiction services
to expand their knowledge of effective treatment and after-care for individuals addicted to opioids.
The New Hampshire Training Institute on Addictive Disorders offers low-cost trainings open to
the public, including trainings on the physiology of addiction, evidence-based treatment, recovery
support services, and drug trends. Additionally, the New England School of Addiction Studies
and the Addiction Technology Transfer Center at Brown University are regional resources
offering professional development and training in addiction, including problem identification and
referral, evidence-based treatment for opioid addiction, and related topics.

PROFESSIONAL DEVELOPMENT & TRAINING
1:4

Increase educational requirements for those seeking to enter the health and
medical field

Although several colleges and universities in New Hampshire have or are considering specialized
coursework in addiction, it is recommended that all post-secondary educational programs
preparing students for work in the health and medical professions expand or adjust required
coursework to include training on addiction, prescription drug abuse, and related topics to increase
the general knowledge of the health care workforce regardless of specialization. Similarly, it is
recommended that medical schools require adequate training of medical students in pain
management, the physiology of addiction, and its classification as a chronic, relapsing brain
disease.

PROFESSIONAL DEVELOPMENT & TRAINING
Increase professional collaboration between providers of primary care,
1:5 behavioral health, addiction treatment, substance abuse prevention, and
alternative therapies
During the Prescription Drug Abuse Strategy Summit held October 3, 2011, primary care and
addiction treatment professionals recognized the communication barriers between the fields of
practice that may be hampering referrals to treatment or recovery support services. Interagency
coordination is recommended to facilitate bi-directional referrals and care coordination between
primary care and addiction treatment and recovery. Substance abuse prevention services may also
play a role in serving individuals and families seeking to recover from addiction.
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PUBLIC EDUCATION & AWARENESS
Provide education to all patients and clients regarding the risks and warning
1:6 signs of prescription drug abuse, proper storage and disposal of medications,
and identify resources available for addiction treatment or recovery services
Patient education is one means of growing public awareness of the potential harm of prescription
drugs, particularly the risk of abuse and dependence and the potential harm of over-medicating.
Providing meaningful information on risks and warning signs of dependence, the interactions of
alcohol and other drugs with prescription medications, and when to contact a prescriber to discuss
concerns is a vital component of patient education. Because prescription drug misuse is a growing
epidemic, health and medical professionals should consider disseminating educational materials to
patients in an overt way, such as through a direct conversation and proffered materials, in addition
to passive means such as posters and brochures available in a waiting room.

In addition to information on risk of abuse and safe storage and disposal, patients should receive
information on accessing treatment and recovery services if a problem is identified. Implementing
this strategy may also encourage partnerships between primary care or other health settings and
addiction treatment and recovery practitioners in the community.

PRESCRIBING & DISPENSING
1:7

Prescribers should check a patient’s prescription history before prescribing
controlled substances

Prescribers should use available means to check a patient’s history for signs of abuse before
prescribing controlled drugs. Although a centralized database such as a prescription drug
monitoring program discussed in other sections of this plan is one means, prescribers may use
electronic health records to look for indications of abuse or drug-seeking behavior. In the absence
of an electronic means, doctors may contact
pharmacists directly to confer on individual cases.
Once a centralized database is established for
physicians to utilize in support of this
recommendation, dispensers must report the
dispensing of prescription medication in a way that
makes this information readily available in real-time
for effective use by prescribers. By reviewing a
patient’s history in real-time, opportunities for abuse
or diversion will be reduced.
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Statistics show that most prescription drugs being abused are accessed through friends or family
members. Patient education should include information on the importance of storing medication
in places that are not visible or accessible to others. In addition, education should include proper
means to dispose of unused medications such as local Take-Back events or secure drop boxes.
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PRESCRIBING & DISPENSING
1:8

Prescribers should screen for substance abuse as part of standard clinical
examination and assessment

Health & Medical Recommendations

Given that approximately one in ten adults (9.58%) in New
Hampshire meet the criteria for abuse or dependence on alcohol or
other drugs,28 prescribing practices should include brief screenings
for substance abuse or a substance abuse history, particularly when
a prescription for opioids may be considered. A brief screen
provides an opportunity for a discussion of a patient’s history of
substance use and consideration of the potential impact a
prescription medication may have on a patient’s use or sobriety,
allowing for a substance use disorder to be considered in
determining a strategy for the presenting medical condition.

PRESCRIBING & DISPENSING
1:9

Prescribers should provide medication guides and counseling to patients
relative to potential harm, including addiction

Patient education should be provided whenever an opioid or any abusable medication is
prescribed, detailing not only the risk of harm of taking the prescription in a way other than
prescribed but also encouraging safe storage and disposal of unused medications to minimize
possible harm to others. In particular, access to prescription drugs should be minimized to protect
people, including youth, who may be seeking a recreational high and to protect against accidental
or inappropriate use.

PRESCRIBING & DISPENSING
1:10

Prescribers should closely evaluate, monitor and even test patients for
prescription drug misuse and abuse

In light of the prevalence of substance use disorders and the growing epidemic of prescription
drug misuse and abuse, it is recommended that prescribers consider a means to effectively monitor
patients who have been prescribed abusable drugs, particularly opioid pain relievers. One method
that some New Hampshire clinics have adopted is patient contracts, discussed in Recommendation
1:15 of this section. Contracts allow for ongoing testing and monitoring of patients to ensure
opioids are taken as prescribed. See also Appendix C for a sample patient contract currently being
used in New Hampshire to monitor patients who may be at risk for misuse or abuse.
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STORAGE & DISPOSAL
1:11

Patient education should include information about proper
storage and disposal of unused medications

As mentioned in the prescriber recommendations above, patient education
should be provided whenever an opioid or any abusable medication is
prescribed, encouraging safe storage and disposal of unused medications
to minimize possible harm to others. In particular, access to prescription
drugs should be minimized to protect young people who may be seeking a recreational high and
to protect against theft, and accidental or inappropriate use.

STORAGE & DISPOSAL

The success of state and local Take-Back events hosted by partnerships between law enforcement
agencies, community anti-drug coalitions, pharmacies, and other organizations have underscored
the abundance of unused medications in homes that may be accessed by drug seekers or that may
pose a risk as a result of accidental or inappropriate use or abuse. Support for these initiatives by
health and medical professionals will help send a consistent message to individuals and
communities about the risks of prescription medication misuse, abuse and misdirection.

DEA’s Third National Prescription Drug Take-Back Event Collects 188.5 Tons
NOV 03 - (WASHINGTON, D.C.) – Americans participating in the U.S. Drug Enforcement Administration’s (DEA’s)
third National Prescription Drug Take-Back Day on October 29, 2011, turned in more than 377,086 pounds
(188.5 tons) of unwanted or expired medications for safe and proper disposal at the 5,327 take-back sites that
were available in all 50 states and U.S. territories. When the results of the three Take-Back Days to date are
combined, the DEA and its state, local, and tribal law-enforcement and community partners have removed 995,185
pounds (498.5 tons) of medication from circulation in the past 13 months.
According to the Centers for Disease Control and Prevention, enough prescription painkillers were prescribed in
2010 to medicate every American adult around-the-clock for one month. Purging America’s home medicine
cabinets of unwanted or expired medications is one of four action items outlined in the national
strategy for reducing prescription drug abuse and diversion.
Excerpted from http://www.deadiversion.usdoj.gov/drug_disposal/takeback/takeback_102911.html
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Health and medical staff and facilities should promote and support local
1:12 “Take-Back” events to encourage safe and regular disposal of unused
medications
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STORAGE & DISPOSAL
1:13 Pharmacies may consider serving as medication disposal sites
This recommendation is included to encourage exploration of opportunities to create a safe means
to collect and dispose of unwanted medications to reduce environmental access and availability of
prescription drugs. Pharmacies, however, are precluded from serving as medication disposal sites
by federal law that is currently under review for possible changes that may allow them to serve in
this capacity in the future. In the Safety & Law Enforcement section of this plan it is also noted
that local police departments may serve as a secure location for permanent drop locations as they
have secure areas and existing protocols for proper disposal.

Health & Medical Recommendations

SURVEILLANCE & MONITORING
1:14

Prescription drug monitoring should be instituted by means of a centralized
database accessible to prescribers and dispensers

As of May 2011, Prescription Drug Monitoring Program (PMP) legislation has been adopted in
48 of 50 states, leaving New Hampshire as one of two states in the country without an electronic
database accessible to prescribers and dispensers to monitor a patient’s prescription drug history.
Please see the Government section of this report for more information about the content and status
of this pending legislation in New Hampshire.
For more information about prescription drug monitoring,
visit the PMP Center for Excellence at Brandeis University.

www.PMPexcellence.org

SURVEILLANCE & MONITORING
Prescribers and prescribing facilities may consider patient contracts
1:15 and other protocols to monitor and detect prescription drug diversion
and/or abuse
Several health care practices in the state have instituted patient contracts or patient agreements for
those patients who are being prescribed narcotics over a period of time for chronic conditions or
for those patients who may have a history of or potential for prescription drug misuse or abuse.
Contracts may require that patients only fill prescriptions at one specified pharmacy, that they
submit to pill counts or urine testing when requested, or other measures to deter abuse. Please see
Appendices C and D of this report for sample contracts and protocols used in New Hampshire.
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Weeks Medical Center – Lancaster, NH
Weeks Medical Center instituted patient contracts in 2010 for patients who were prescribed opioid pain relievers
to treat chronic conditions. The contracts stipulated the risks associated with use and the consequences of violating
the contract either as a result of misuse, abuse or diversion. Patients who are found to
be in violation of the contract are terminated as pain patients but may remain under
the care of the medical center for other health care needs. Please see Appendix C
for a copy of the patient contract used by Weeks Medical Center.

SURVEILLANCE & MONITORING
1:16

Dispensers should take increased precautions to protect stock and prevent
unlawful access to prescription drugs

Ossipee

SURVEILLANCE & MONITORING
1:17

Licensing boards and authorities should monitor, investigate and enforce
policies and encourage enhanced protocols to deter abuse and diversion

The New Hampshire Board of Pharmacy, the New
Hampshire Board of Nursing, and the New
Hampshire Board of Medicine all support the
monitoring, investigation and enforcement of
policies, laws and protocols to deter abuse and
diversion. Each provides access to professional
development and training to support practitioners
in ethical decision-making and abuse deterrence.
Their training calendars are available on the web
at the links provided at the end of this section.
Licensing boards may also consider increasing
public and professional awareness of how to
register a concern regarding improper, unsafe, or
questionable prescribing or dispensing practices.
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The New Hampshire
Board of Pharmacy
issues Pharm-ALERTs that are faxed to all pharmacies with
intelligence reports from state law enforcement regarding
immediate threats. The alerts provide the means of
diversion (e.g. a stolen prescription pad from a specific
hospital), the names under which fraudulent prescriptions
have been sought, the doctor’s name being used on the
prescription, and the drugs being sought. These alerts
have been effective in notifying dispensers of fraudulent
activity discovered by authorities.

Health & Medical Recommendations

Pharmacies and other dispensaries are increasingly becoming targets
of theft and fraud. For example, in 2009, a Rite Aid pharmacy in
Ossipee, NH, was burglarized four times by individuals seeking pain
medication. Enhanced safety precautions and anti-theft measures are
necessary to increase the safety of pharmacists, pharmacy technicians
and the public and to prevent unlawful access to controlled drugs.
Although the quantity of prescription drugs being stolen from
pharmacies is on the decline in New Hampshire29, this may be due to
increased enforcement and/or alternative means to divert drugs.
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Health & Medical Recommendations

1:18

Referral to appropriate intervention or treatment should be provided if
indications of abuse or dependence exist

One patient screening and referral model that has gained attention for its outcomes is the evidencebased Screening, Brief Intervention and Referral to Treatment (SBIRT) approach endorsed by the
U.S. Substance Abuse and Mental Health Administration (SAMHSA). The model encourages a
brief screening for alcohol or other drug abuse in primary practice, emergency rooms, or other
settings. A screening indicating potential alcohol or drug abuse leads to an additional set of
questions that determine if a practitioner should provide a brief intervention, such as motivational
interviewing, or if referral to more intensive intervention or treatment is necessary. Although
some service delivery systems, such as the state’s community mental health system, does conduct
brief alcohol and drug screenings of all clients, universal screening is not yet a widespread
practice. Attention should be given within other care systems, such as the community health
center system and hospital emergency rooms, to implement screening and appropriate
interventions more broadly.
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RESOURCES
PRESCRIBING
Guidelines for the Use of Controlled Substances in the Treatment of Pain
Adopted by the New Hampshire Medical Society, July 1998

http://www.nhms.org/resources/painmgmt.php

Updated guidelines
expected in Spring, 2012.

The New Hampshire Board of Nursing provides continuing education opportunities for nurses, including
Advance Practice Nurses licensed to prescribe medications.

http://www.nh.gov/nursing/education/index.html
NH Department of Corrections, Division of Medical and Forensic Services, Clinical Guidelines for
Prescribing Opioids for Treatment of Chronic Pain, May 2009

http://www.nh.gov/nhdoc/documents/6-41.pdf
The Federation of State Medical Boards (FSMB), Responsible Opioid Prescribing: A Physician’s Guide

FSMB Model Policy for the Use of Controlled Substances for the Treatment of Pain, May 2004

http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf
DISPENSING
The New Hampshire Board of Pharmacy provides continuing education for pharmacists and pharmacy
technicians in a wide range of topics to prevent fraudulent access and to respond to identified problems.

http://www.nh.gov/pharmacy/pharmacists/ce_programs.htm
Massachusetts College of Pharmacy – Manchester, NH

http://www.mcphs.edu
DRUG DIVERSION
The NH Drug Diversion Unit trainings to prevent unlawful diversion of prescription medications

http://www.nh.gov/safety/divisions/nhsp/isb/narcotics/index.html
PATIENT EDUCATION
The American Society of Addiction Medicine introduced the Physician Clinical Support System for
Primary Care (PCSS-P), a free, nationwide service to help primary care providers seeking to identify and
advise their patients regarding alcohol and drug abuse before they evolve into life-threatening conditions.

http://www.nida.nih.gov/nidamed/pcss.php
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http://www.fsmb.org/pain-overview.html

January 2012

Call to Action: Responding to New Hampshire’s Prescription Drug Epidemic

PUBLIC EDUCATION & AWARENESS
The New Hampshire Department of Health and Human Services' Injury Prevention Program

http://www.dhhs.nh.gov/dphs/bchs/mch/injury.htm
The Northern New England Poison Control Program - New Hampshire

http://www.mmc.org/mmc_body.cfm?id=3090
Northeast Regional Injury Prevention Network - Poison Data Book (January 2004)

http://www.ask.hrsa.gov/downloads/poison_book.pdf
New Hampshire Alliance for the Mentally Ill (NAMI-NH)

http://www.naminh.org/education/suicide-prevention

Health & Medical Resources

SCREENING & BRIEF INTERVENTIONS
The National Institute on Drug Abuse (NIDA) Centers of Excellence for Physician Information
provides science-based resources to help physicians identify patient drug use early and to prevent it from
escalating to abuse or addiction as well as identify and refer patients in need of specialized addiction
treatment.

http://www.drugabuse.gov/coe/
Online Screening, Brief Intervention and Referral to Treatment (SBIRT) training through the National
Institute on Drug Abuse (NIDA).

http://www.sbirttraining.com/sbirtcore
ADDICTION TREATMENT
New Hampshire Training Institute on Addictive Disorders

http://www.nhadaca.org/training.html
New England School of Addiction Studies

http://www.neias.org/SATneias.html
New England Addiction Technology Transfer Center Training Calendar

http://www.nattc.org/regcenters/trainingevents.asp?rcid=8&ViewType=
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Safety & Law Enforcement Recommendations Overview
PROFESSIONAL DEVELOPMENT & TRAINING
2:1

Increase the number of trainings and professional development opportunities available to and
accessed by law enforcement and other safety personnel

PUBLIC EDUCATION & AWARENESS
Develop and disseminate legal bulletins specific to prescription drug abuse and diversion

STORAGE & DISPOSAL
2:3

Participate in local Take-Back events to collected unused or unwanted medication

2:4

Serve as permanent disposal sites for the public

SURVEILLANCE & MONITORING
2:5

Continue and expand investigation and prosecution resources and efforts specific to
prescription drug diversion

2:6

Designate an officer as a prescription drug diversion specialist for targeted training,
community liaison, intelligence bulletins, and coordination of effort
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Safety & Law Enforcement Recommendations

Local Law Enforcement - Emergency Medical Technicians - First Responders
Drug Diversion Specialists - Police Standards & Training

PROFESSIONAL DEVELOPMENT & TRAINING
2:1

Increase the number of trainings and professional development opportunities
available to and accessed by law enforcement and other safety personnel

Diversion of prescription medication from its original recipient and/or intent is unlawful and
requires unique law enforcement practice strategies distinct from those developed for illicit drugs.
Determining the means and methods by which drug-seekers may be acquiring prescription drugs
requires specialized training and proactive enforcement. Professional development and training
for law enforcement and safety professionals should include training in prescription forgery and
other diversion tactics such as doctor shopping, illicit prescription drug sales, and specialized
investigation and enforcement. The New Hampshire Department of Safety’s Drug Diversion Unit
has developed a curriculum for trainings through the Police Standards and Training Council and
other training providers.
In addition, the New Hampshire Division of Liquor Enforcement is leading the state’s training
effort relative to Drug Recognition Experts and Advanced Roadside Impairment Detection
Enforcement (ARIDE) to help deter motor vehicle impairment due to prescription drug abuse or
other substance abuse (See Commitments to Action on page 73). The state’s federal partners also
provide training opportunities for law enforcement. Federal training partners include the New
England High Intensity Drug Trafficking Area and the U.S. Drug Enforcement Agency. Links to
these and other resources are provided at the end of this section.
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According to Section 309 of the federal Uniform Controlled Substances Act, drug diversion is the
transfer of a controlled substance from a lawful to an unlawful channel of distribution or use.
Because prescription drugs are legal substances when prescribed, dispensed, and used
appropriately, enforcement of drug diversion laws is unique and requires a proactive commitment
by law enforcement agencies to investigate and prosecute offenders.
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PUBLIC EDUCATION & AWARENESS
2:2

Develop and disseminate legal bulletins specific to prescription drug abuse
and diversion

Safety & Law Enforcement Recommendations

Legal bulletins can be an effective means to highlight the scope of the epidemic on a consistent
basis and can be disseminated to a wide range of state and community stakeholders. The New
Hampshire Attorney General’s office and the New Hampshire Department of Safety are
committed to summarizing prevalence and other statistics on prescription drug diversion and
enforcement regularly to keep communities informed (see Commitments to Action on page 73).
Local and county law enforcement agencies should consider similar practices to share information
on investigations, prosecution, drug-seeking behaviors and tactics, and safety precautions. Legal
bulletins can be disseminated through existing list serves, fax alert networks, public health
networks, social media, and other communication routes.

STORAGE & DISPOSAL
2:3

Participate in local Take-Back events to collect unused or unwanted
medication

Take-Back events are defined by the U.S. Drug Enforcement Administration as organized
collection events designed to reduce the amount of unwanted or unused pharmaceutical products
that may pose a risk to public health and safety, that may be accessible to diversion, or that
otherwise may be disposed of in a manner that does not comply with State or Federal laws or
regulations.30 Once a controlled drug leaves the possession of the individual to whom it was
prescribed, law enforcement are often the only institution with the legal authority to handle and
dispose of the drugs. Therefore, the participation of local and county law enforcement has been
critical to the success of the three national Take-Back events that have been hosted in New
Hampshire communities over the past 15 months.
Because of legal concerns raised regarding the handling of the prescription drugs by individuals
other than law enforcement during the Take-Back events, the New Hampshire Office of the
Attorney General crafted legislation to accommodate the activities of the Take-Back events safely
and legally. This legislation, introduced as House Bill 71, was passed by the New Hampshire
Legislature this year and allows for “communities and private entities in conjunction with law
enforcement officers to establish controlled and non-controlled pharmaceutical drug take-back
programs” and requires rulemaking by the Department of Justice, the Board of Pharmacy, the
Department of Safety, and the Department of Environmental Services to provide established
guidelines for such Take-Back events. The legislation allows for individuals to drop off
medications anonymously and lessens the disposal restrictions for drugs collected in this venue
that are much more stringent as stipulated in RSA 318-B:17 for illicit drug disposal.31 The formal
rulemaking process has been initiated by the Department of Justice.
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STORAGE & DISPOSAL
2:4 Serve as permanent disposal sites for the public

SURVEILLANCE & MONITORING
2:5

Continue and expand investigation and prosecution resources and efforts
specific to prescription drug diversion

The new era of prescription drug diversion has demanded a quick and specialized response from
the law enforcement and safety sector at a time when resources are scarce and the demands on
local, county and state law enforcement are high. Yet law enforcement officials in New
Hampshire are more committed than ever to developing an adequate and effective response to the
growing epidemic of prescription drug abuse. This commitment has led to specialized trainings
offered through the Department of Safety’s Drug Diversion Unit and through other state, regional
and federal resources listed at the end of this section. Local and county law enforcement and
safety officials are called to prioritize the epidemic of prescription drug abuse through expanded or
enhanced diversion enforcement and prosecution and to collaborate with local, state and federal
organizations to leverage resources in support of this strategy.

SURVEILLANCE & MONITORING
2:6

Designate an officer as a prescription drug diversion specialist for targeted
training, community liaison, intelligence bulletins, and coordination of effort

Designating a specific officer(s) to serve as a liaison between state training and response efforts
and community networks is an approach that has been successful with other alcohol and drug
efforts such as underage drinking. A designated officer can coordinate comprehensive training
schedules within their local department, serve as a “train the trainer” to bring specialized resources
to his/her department, serve on community task forces working to prevent and reduce prescription
drug abuse, and serve as a conduit of bi-directional information sharing such as through legal
bulletins or data mining and analysis. A designated officer could also be trained as a Drug
Recognition Expert to assist in prescription drug abuse cases when appropriate.
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Safety & Law Enforcement Recommendations

Many local police departments and safety units have supported local Take-Back initiatives in New
Hampshire as one-time events, but several police departments across the state have or are
considering serving as permanent drop-off locations for the public in support of prescription drug
abuse prevention. Local police departments have been meeting the challenge of the prescription
drug diversion through specialized enforcement but are also committing resources to serve as
permanent disposal sites because they are uniquely suited to do so through their authority to
receive and properly dispose of controlled drugs. In addition, locating a drop-box at a police
department minimizes safety concerns relative to drug-seekers who may attempt to gain access to
prescription drugs that have been dropped off for disposal. Once a permanent drop-off location is
established, as in Keene, New Hampshire, local coalitions, health and medical professionals,
schools, businesses, and other community organizations can begin to promote the site to the public
to provide ongoing education and awareness and to reduce availability of unused medications.
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Community Spotlight: Take-Back Events in the Monadnock Region
For each of the three National Take-Back events held since the strategy was initiated by the
U.S. Drug Enforcement Agency, Monadnock Voices for Prevention and its government partner,
Cheshire County, have mobilized law enforcement agencies, schools, community organizations,
health care partners and pharmacists to assist in the region-wide effort to reduce
environmental access to prescription drugs by encouraging local residents to drop
off unused medications at participating police departments. The momentum has
led to a permanent secure drop-off location at a local police department sponsored
by a local Rotary Club. In the Monadnock region, the one-day events have so far
led to over 1,000 pounds of unused medications being safely disposed of.
In the April 2011 Take-Back event, New Hampshire, with a population of only
1.3 million collected 10% of all medications gathered across the U.S. in
similar events that day. For more information about Monadnock Voices for
Prevention’s prescription drug abuse prevention efforts, please visit:
http://www.monadnockvoices.org
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RESOURCES
PROFESSIONAL DEVELOPMENT & TRAINING
The NH Drug Diversion Unit trainings to prevent unlawful diversion of prescription medications

http://www.nh.gov/safety/divisions/nhsp/isb/narcotics/index.html
New Hampshire Police Standards and Training Council training opportunities for law enforcement

http://www.pstc.nh.gov/TrainingCalendar.pdf
National Guard Northeast Counterdrug Training Center

http://www.counterdrug.org/NCTC/nctc.html
New England High Intensity Drug Trafficking Area (HIDTA) training opportunities

http://www.hidta.org/Training/training.asp

http://www.justice.gov/dea/programs/training/part8.html
The NH Division of Liquor Enforcement drug recognition expert training program and alcohol/drug
training for alcohol licensees

http://www.nh.gov/liquor/enforcement.shtml

Contact: Sgt. Chris Hutchins (603) 271-3521

GENERAL TECHNICAL ASSISTANCE
National Association of Drug Diversion Investigators

http://associationdatabase.com/aws/NADDI/pt/sp/resources_links
U.S. Department of Justice, Drug Enforcement Agency

http://www.deadiversion.usdoj.gov
TAKE-BACK PROTOCOLS
National Take-Back Network

http://www.takebacknetwork.com/pdf/Safe_Disposal_of_Unused_Controlled_Substances.pdf
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Safety & Law Enforcement Resources

U.S. Drug Enforcement Agency training opportunities
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EDUCATION
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Education Recommendations Overview
PROFESSIONAL DEVELOPMENT & TRAINING
3:1

Increase the number of trainings and professional development opportunities available to
and accessed by school personnel

PUBLIC EDUCATION & AWARENESS

3:3

Support the implementation of evidence-based health curricula that address prescription
drug misuse and abuse

STORAGE & DISPOSAL
3:4

Help promote community Take-Back events to collect unused medication

3:5

Ensure that health and nursing services implement safe storage and dispensing of
medications to deter abuse or diversion

SURVEILLANCE & MONITORING
3:6

Continue school-based data collection to gauge the prevalence and perceptions of
prescription drug misuse and abuse

3:7

Establish, communicate and enforce drug-free policies and comprehensive approaches that
include prevention of prescription drug misuse or abuse

3:8

Provide problem identification and referral for youth and adults within educational systems
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3:2

Support the dissemination of public service announcements and bulletins to youth,
students, parents, and communities relative to prescription drug misuse, abuse and
diversion
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Education Recommendations

School Safety Officers - Campus Health Services - School Nurses - Campus Police
Student Assistance Counselors - College Counseling Departments
Staff & Administration

PROFESSIONAL DEVELOPMENT & TRAINING
Increase the number of trainings and professional development opportunities
available to and accessed by school personnel

Professional development and training for school nurses, health teachers, health services staff,
administrators, school safety officers, alcohol and drug counselors and other staff will increase
awareness of prescription drug abuse as a preventable epidemic and will provide specific
strategies that school- and college-based health and safety professionals can implement to address
misuse and abuse effectively. Training is available from a wide range of stakeholders in the state
and region. Links to resources for the education sector are listed at the end of this section and
throughout this report. For example, the New Hampshire Board of Nursing provides online
training for school and campus nurses while the New Hampshire Drug Diversion Unit provides
training appropriate for school resource officers and campus police. See also the Commitments to
Action section of this document beginning on page 73 for the role of the New Hampshire
Department of Education in professional development and training.

PUBLIC EDUCATION & AWARENESS
Support the dissemination of public service announcements and bulletins
3:2 to youth, students, parents, and communities relative to prescription drug
misuse, abuse and diversion
Public and private schools and institutions of higher education have effective, well-established
communication channels that can be leveraged in service to the state’s Call to Action for the
purposes of educating youth and young adults on the risks associated with prescription drug
misuse, abuse and diversion. During the development of this plan it was noted that youth
leadership and advocacy groups such as local Youth to Youth, Project Success or Peer Outreach
chapters can play an effective role in helping to communicate risks to their peers and the
community-at-large. Communication channels may take the form of newsletters, emails, open
letters to parents or campus communities, websites, social media, poster campaigns, blogs, and
other forms.
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It is recommended that schools, colleges and universities respond favorably to requests from state
and community stakeholders to disseminate information on prescription drug abuse and actively
schedule their own regular information dissemination on prescription drug abuse. Sources of
information for such bulletins and messaging are provided at the end of this section.

PUBLIC EDUCATION & AWARENESS

Education Recommendations

3:3

Support the implementation of evidence-based health curricula that address
prescription drug misuse and abuse

Elementary, middle and high schools as well as colleges and universities typically provide some
form and duration of health education as a component to general education requirements. It is
recommended that schools at all levels review their health curricula to ensure that alcohol and
drug abuse is adequately covered as a health topic priority, that the curricula being used have
evidence of effectiveness in increasing knowledge of risks (physical and otherwise) of alcohol
abuse and drug use, and that the curricula specifically address prescription drug misuse and abuse.
One comprehensive approach to prevention and early intervention that was implemented widely in
New Hampshire schools before recent budget reductions is Project Success, an approach that
combines youth and parent education with policy revision, more intensive prevention for high-risk
populations, and early intervention strategies in the school setting. Resources to assist schools in
this strategy are provided at the end of this section.

STORAGE & DISPOSAL
3:4 Help promote community Take-Back events to collect unused medication
As mentioned in other sections of the Call to Action, Take-Back events were established by the
U.S. Drug Enforcement Agency to reduce environmental access to prescription drugs that pose
significant risk to those who may misuse or abuse them. New Hampshire communities have
participated in three such events over the last 15 months, with unprecedented amounts of
medications collected and disposed of safely. Schools can help promote these events to parents
and community members to build awareness and decrease unsafe access to narcotics and other
prescription drugs.

STORAGE & DISPOSAL
3:5

Ensure that health and nursing services implement safe storage and
dispensing of medications to deter abuse or diversion

As mentioned in the Health & Medical section of this document, safe storage of prescription
medications is a means to deter abuse and diversion. School and campus nursing or health
services may store medications for students and monitor the dispensing of prescribed medications.
Schools and campuses should ensure medications are safely stored and regularly inventoried.
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SURVEILLANCE & MONITORING
3:6

Continue school-based data collection to gauge the prevalence and
perceptions of prescription drug misuse and abuse

Valuable data are collected from youth and young adults through surveys administered in school
settings in New Hampshire as these settings reach the widest cross-section of children and young
adults. The Youth Risk Behavior Survey, Teen Assessment Project survey, Communities That
Care, and Pride surveys are all reliable instruments administered at the middle and high school
level to collect local prevalence and perception data on alcohol and drug abuse, including
prescription drug abuse. Additionally, the New Hampshire Higher Education Consortia has an
alcohol and other drug committee that oversees the administration of the New Hampshire Higher
Education Alcohol, Tobacco and Other Drug Survey at participating colleges and universities.
These biannual surveys provide valuable data to health and safety stakeholders to design effective,
data-driven responses to alcohol and drug abuse risks and trends. It is recommended that schools
continue to allow for this data collection in school settings and to support the use of data to inform
school and community responses to identified behaviors and misperceptions.

3:7

Establish, communicate and enforce drug-free policies and comprehensive
approaches that include prevention of prescription drug misuse or abuse

Comprehensive school-based approaches to substance abuse include effective, well-monitored and
consistently enforced policies to define, prevent, intervene in and appropriately address alcohol
and other drug problems. As mentioned earlier in this section, Project Success is an evidencebased comprehensive approach that many New Hampshire schools have adopted to incorporate
youth leadership, parent education, policy change and enforcement, early intervention for highrisk youth populations, and referral to treatment or recovery services for students with identified
alcohol or drug problems.

SURVEILLANCE & MONITORING
3:8

Provide problem identification and referral for youth and adults within the
educational systems

Problem identification and referral has been an effective approach to addressing alcohol abuse and
drug use with those misusing and abusing substances. Schools, colleges and universities are in a
unique position to identify individuals early and to provide brief interventions or referrals to more
comprehensive services. In the Health & Medical section of this report, an evidence-based
approach to problem identification and referral known as SBIRT (Screening, Brief Intervention
and Referral to Treatment) is presented as one approach that has strong evidence of effectiveness
in emergency room and primary care settings. SBIRT or a similar approach can be applied in
school settings when a student is found to be in violation of an alcohol or drug policy or who
requires medical attention as a result of alcohol abuse or drug use, including prescription drug
misuse or abuse.
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RESOURCES
PRESCRIBING & MONITORING
The New Hampshire Board of Nursing provides continuing education opportunities for nurses, including
school and campus nurses.

http://www.nh.gov/nursing/education/index.html
SCREENING & BRIEF INTERVENTIONS
The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA)’s SBIRT initiative
has included grant programs, policy briefs, and training to encourage the implementation of SBIRT in a
wide range of settings from emergency rooms to school-based health centers

http://www.samhsa.gov/samhsanewsletter/Volume_17_Number_6/SBIRT.aspx
DRUG DIVERSION

Education Resources

The NH Drug Diversion Unit trainings to prevent unlawful diversion of prescription medications

http://www.nh.gov/safety/divisions/nhsp/isb/narcotics/index.html
LAW ENFORCEMENT TRAINING
The NH Division of Liquor Enforcement drug recognition expert training program and alcohol/drug
training for alcohol licensees

http://www.nh.gov/liquor/enforcement.shtml

Contact: Sgt. Chris Hutchins (603) 271-3521

GENERAL TECHNICAL ASSISTANCE (COLLEGES & UNIVERSITIES)
U.S. Department of Education’s Higher Education Center for Alcohol, Drug and Violence Prevention
provides recommendations for college campus responses to Rx drug abuse

http://www.higheredcenter.org/services/assistance/topics/prescription-drug-abuse-among-college-students-0
PUBLIC EDUCATION & AWARENESS
The White House Office of National Drug Control Policy oversees “Parents – the Anti-Drug” and other
education and awareness campaigns, providing web links, print materials and other resources to support
school- and community-based awareness and outreach

http://www.theantidrug.com/drug-information/otc-prescription-drug-abuse/prescription-drug-rx-abuse/default.aspx
NIDA for Teens: PeeRx, an engaging website for youth, teachers, and parents to learn about prescription
drug abuse

http://teens.drugabuse.gov/peerx/
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Business Recommendations Overview
PROFESSIONAL DEVELOPMENT & TRAINING
4:1

Increase the number of trainings and professional development opportunities available to
and accessed by the workforce and employers

PUBLIC EDUCATION & AWARENESS
4:2

Promote public education and awareness within the workplace

STORAGE & DISPOSAL
Help promote community Take-Back events to collect unused medication

4:4

Ensure that worksite policies and practices articulate safe storage and use of medications to
deter abuse or diversion

SURVEILLANCE & MONITORING
4:5

Establish, communicate and enforce drug-free workplace policies that include prevention
of prescription drug misuse or abuse

4:6

Provide problem identification and referral for employees
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Business Recommendations

Risk Management - Health Educators - Employee Assistance Programs
Safety Compliance Officers - Human Resource Departments
Senior Management - Business Owners & Operators

PROFESSIONAL DEVELOPMENT & TRAINING
4:1

Increase the number of trainings and professional development opportunities
available to and accessed by the workforce and employers

Professional development and training provide education and strategies to ensure workers are
aware of the risks of prescription drug abuse and the consequences of misuse and abuse in the
workplace. Professional development and training of risk managers, supervisors, and human
resource departments also encourage appropriate enforcement of workplace standards and
policies.

PUBLIC EDUCATION & AWARENESS
4:2 Promote public education and awareness within the workplace
Businesses can support public education and awareness through regular employee education
programs that focus on worksite wellness and safety. Company websites and health and wellness
initiatives offered by employers can be a means to communicate information about the health risks
of alcohol and drug use, including prescription drug misuse and abuse.
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Employers are often as affected by the substance use of their employees as the employees’
families and friends. Of the estimated 19.3 million current illicit drug users aged 18 or older in
2009, 12.9 million (66.6%) were employed either full- or part-time.32 The effects of workers who
abuse alcohol, prescription medications or illicit drugs can range from lost work time to unsafe
work conditions. Employers, however, hold powerful tools and leverage to prevent and deter
substance use through workplace policies and employee assistance programs. The following
strategies are recommended for businesses and employers to consider in support of the state’s
commitment to prevent and reduce prescription drug misuse and abuse and its harmful
consequences.
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STORAGE & DISPOSAL
4:3 Help promote community Take-Back events to collect unused medication
Businesses, particularly those in the health or safety field, can help promote community TakeBack events and even contribute resources for their successful implementation. Resources may
take the form of sponsorship of space, promotional materials, or equipment to support such events.
For example, a local Rotary Club in the Keene, NH area provided funding to support a permanent
drop-box at a local police department for Take-Back opportunities outside of special events.

STORAGE & DISPOSAL

Business Recommendations

4:4

Ensure that worksite policies and practices articulate safe storage and use
of medications to deter abuse or diversion

Employers can promote safe storage and medication use at job sites to deter abuse or diversion.
Policies may require that employees inform employers if they are taking prescribed narcotics
during work hours and receive guidelines on how and where to store and access medications on
the job site when necessary. It is critical, however, that employers respect employees' rights and
that policies do not interfere with privacy considerations.

SURVEILLANCE & MONITORING
4:5

Establish, communicate and enforce drug-free workplace policies that
include prevention of prescription drug misuse or abuse

Model workplace policies include educating employees about the health and productivity hazards
of alcohol abuse, prescription drug misuse and abuse, and illicit drug use. Company wellness
programs and employee assistance programs can be leveraged to communicate company policies
and ongoing health and safety promotion. More comprehensive policies may also include
mandatory random drug testing; clearly communicated consequences for any alcohol or drug
abuse; rules for how and where allowable prescription drugs should be stored or accessed during
work hours; mandatory participation in regular education programs regarding the harm of
addiction and the impact of substance use on worker productivity, workplace safety, and other
considerations; and consistent enforcement of all workplace policies.

SURVEILLANCE & MONITORING
4:6 Provide problem identification and referral for employees
As noted in previous sections of this document, problem identification and referral is an important
strategy in protecting individuals’ health and safety. Through employee assistance programs or
more informal arrangements within small businesses, brief conversations can allow employers and
supervisors to identify and respond to problems early on. If an employee is at risk of developing a
serious problem, he/she may receive a brief intervention that focuses on raising their awareness of
substance abuse risks and motivating them to change their behavior while those who may need
more extensive treatment receive referrals to specialty care.33
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RESOURCES
MODEL WORKPLACE POLICES
U.S. Department of Labor “Policy Builder” provides guidance in developing and maintaining an
effective workplace policy; samples included.

http://www.dol.gov/elaws/asp/drugfree/drugs
EMPLOYEE EDUCATION
U.S. Department of Labor Employee Education curriculum provides employee education modules on
drugs and alcohol in the workplace, including business impact and safety. Download educational programs
for use in the workplace.

http://www.dol.gov/asp/programs/drugs/workingpartners/dfworkplace/employee/impact.htm
INFORMATION DISSEMINATION
“Prescription Drug Abuse in the Workplace” – a publication of the U.S. Substance Abuse and Mental
Health Services Administration
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Business Resources

http://workplace.samhsa.gov/pdf/Prescription%20Drug%20Abuse%20Fact%20Sheet.pdf
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GOVERNMENT
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Government Recommendations Overview
PROFESSIONAL DEVELOPMENT & TRAINING
5:1

Support licensing boards in addressing concerns relative to prescribing and dispensing
controlled drugs

PUBLIC EDUCATION & AWARENESS
Lead and/or support a public awareness campaign

5:3

Identify, promote and support evidence-based programs, policies and practices that
communities can adopt to deter abuse

STORAGE & DISPOSAL
5:4

Continue to support state and local opportunities to collect and safely dispose of unused
medication

SURVEILLANCE & MONITORING
5:5

Pass legislation to implement an electronic Prescription Drug Monitoring Program

5:6

Adjust existing state-level data collection to provide greater detail relative to the
prevalence, causes, sources, and consequences of prescription drug abuse

5:7

Provide leadership and oversight in coordinated surveillance, monitoring and strategic
planning

RESOURCE DEVELOPMENT
5:8

Provide reimbursement to health and medical practitioners for Screening, Brief
Intervention and Referral to Treatment (SBIRT)

5:9

Expand funding for treatment to increase access for individuals requiring treatment for
prescription drug abuse

5:10

Consider specialized or “therapeutic” courts that provide culturally sensitive assessments,
treatment and recovery opportunities in place of traditional probation or incarceration
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Government Recommendations

State Lawmakers - County Officials
Local Governance - State Agencies & Commissions

PRESCRIBING & DISPENSING
5:1

Support licensing boards in addressing concerns relative to prescribing and
dispensing controlled drugs

The state government sector provides necessary oversight of prescribing and dispensing practices
through its licensing boards. In New Hampshire, the Board of Medicine, the Board of Nursing
and the Board of Pharmacy exist for the safety and protection of New Hampshire citizens. In light
of the epidemic of prescription drug abuse it is recommended that government leaders and
lawmakers ensure licensing boards have sufficient resources and authority to protect citizens
through well-monitored and enforced prescribing and dispensing practices. Licensing boards
should also encourage citizens and professionals alike to report concerns related to prescribing and
dispensing.

PUBLIC EDUCATION & AWARENESS
5:2 Lead and/or support a public awareness campaign
The New Hampshire Bureau of Drug and Alcohol Services and the public education and
awareness task force of the Governor’s Commission on Alcohol and Drug Abuse work closely
with the Partnership for a Drug Free New Hampshire and the National Guard Counterdrug Task
Force to develop and disseminate public media campaigns and other public service announcements
to prevent and reduce alcohol abuse and other drug use. Continuing and expanding the capacity of
these partnerships and efforts in order to increase the public’s awareness of the dangers of
prescription drug misuse, abuse and diversion is a critical component of an effective state
prevention strategy. All state agencies and divisions can assist in the dissemination of public
service announcements and campaigns relative to prescription drug abuse in service to this Call to
Action.
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Local, county and state governments play a critical role in addressing the prescription drug abuse
epidemic in that they are able to develop effective population-level laws and regulations and to
direct resources to meet identified needs. In spite of the difficult economic pressures at all levels
of government, lawmakers and elected officials can also bring much needed visibility, leadership,
legislation, and collective commitment to combat the growing epidemic in New Hampshire.
Resources in service to local, regional and state government actions are provided at the end of this
section.
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PUBLIC EDUCATION & AWARENESS
5:3

Identify, promote and support evidence-based programs, policies and
practices that communities can adopt to deter abuse

Through the Bureau of Drug and Alcohol Services and its training and technical assistance
contractors, evidence-based programs, policies and practices for schools, businesses, police
departments, medical practices, and other community sectors can be identified and promoted.
In addition, the Bureau’s Regional Network System can be mobilized to support community
sectors in their adoption of evidence-based prevention, intervention, and treatment policies and
programs. Other state agencies such as the New Hampshire Department of Safety, the Department
of Health and Human Services, the Department of Education, the National Guard, the Attorney
General’s Office, state licensing boards, and others may also identify and promote evidence-based
efforts within their fields of practice and specialty in response to this Call to Action.

Government Recommendations

STORAGE & DISPOSAL
5:4

Continue to support state and local opportunities to collect and safely
dispose of unused medication

As mentioned in the Safety & Enforcement section of this document, the New Hampshire Attorney
General supported the passage of legislation (House Bill 71) to allow communities and private
entities in conjunction with law enforcement to conduct local pharmaceutical drug Take-Back
events and programs to collect, store, and dispose of unused controlled and uncontrolled
prescription drugs in a safe and effective manner. The legislation allows for individuals to drop
off medications anonymously and lessens the disposal restrictions for drugs collected in this venue
that are much more stringent as stipulated in RSA 318-B:17 for illicit drug disposal.34 At this
time, the Department of Justice has initiated the formal rulemaking process.

SURVEILLANCE & MONITORING
5:5

Pass legislation to implement an electronic Prescription Drug Monitoring
Program

Legislation to allow for the establishment of an electronic controlled drug prescription monitoring
program (PMP) will provide prescribers and dispensers timely access to information for the
purposes of monitoring patients’ prescriptions. Federal guidelines recommend that Schedule II
through V medications be included in PMPs, although current pending legislation in New
Hampshire includes Schedule II and III drugs only (Please see Appendix G for a list of controlled
drugs by schedule classification). Legislation has been submitted and considered each year since
2008 and is currently in interim study as House Bill 332-FN. The most recent version of the
house-initiated legislation recognizes that prescription drug abuse is a significant problem in the
state and that individuals with substance use disorders may seek controlled drugs from health care
providers. It also articulates that “allowing providers to have access to information suggesting that
their patients have been ‘doctor shopping’ can help them provide better care for these patients.”35
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In December of 2011, the New Hampshire Senate also introduced PMP legislation (SB 286) titled,
Controlled Drug Prescription Health and Safety Program. The recently filed bill states the
General Court’s belief that:
A controlled drug prescription health and safety program that fully complies with
all state and federal Health Insurance Portability and Accountability Act (HIPPA)
privacy and security laws and regulations should be established as a tool to improve
medical treatment. (IV)36
The bill further states that:
a controlled drug prescription health and safety program will reduce patient
morbidity and mortality associated with controlled drugs by providing a secure
program through which the prescriber and the dispenser may access information on
a patient’s controlled drug prescription history. The program established by this act
is designed to create a greater sense of safety, security, and comfort in the health
practitioner-patient relationship when controlled drugs are prescribed. (V)37

The effectiveness of prescription drug monitoring programs has been documented by independent
evaluations of individual states’ programs and by researchers working under contract with the
U.S. Department of Justice. In an independent evaluation of
Kentucky’s PMP program known as KASPER, the University of
Kentucky documented the state’s adoption of a PMP program in
1998 and its enhancement in 2005 to a 24 hour real-time accessible
system (eKASPER). The evaluation found that 86% of prescribers
using the system indicated the information either confirmed a
decision to prescribe a controlled drug or altered their decision.
Only 4% of prescribers who utilized the system indicated that the
information accessed had no impact on their prescribing decisions.38
In an evaluation of 20 states’ PMP programs commissioned by the U.S. Department of Justice,
researchers examined outcomes by PMP type, noting important distinctions between states with
reactive versus proactive monitoring programs. The researchers defined “reactive” programs as
those generating "solicited reports" only in response to a specific inquiry made by a prescriber,
dispenser, or other party with appropriate authority, whereas "proactive" programs were defined as
those generating "unsolicited reports" for identification or investigation or when the system
deemed it was warranted. In this evaluation, researchers found that the presence of a PMP is
associated statistically with a reduction in the per capita supply of prescription pain relievers and
stimulants, and that this in turn reduces the probability of abuse. This finding was evident in states
with both proactive and reactive PMPs, but was stronger in an aggregate of states with proactive
programs.39
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This newly pending legislation in New Hampshire is to include Schedule II through IV controlled
drugs and is sponsored by 15 of the state’s 24 senators.
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Government Recommendations

PMP legislation and resulting implementation of electronic systems to provide access to data on
prescriptions being written and filled for individuals is one of the most universally recommended
and adopted strategies by state governments to combat prescription drug misuse, abuse and
diversion. New Hampshire is one of only two states that have not adopted PMP legislation to
date.

SURVEILLANCE & MONITORING
Adjust existing state-level data collection to provide greater detail relative
5:6 to the prevalence, causes, sources, and consequences of prescription drug
abuse
The State of New Hampshire collects data regularly on the prevalence and perception of
prescription drug misuse and abuse including surveys, death data, criminal offenses, and hospital
and emergency room admissions and discharges. Survey-based data collection includes the state
sample and local sample administration of the Youth Risk Behavior Survey (YRBS) of high
school aged youth and the Behavioral Risk Factor Surveillance System (BRFSS) survey of adults
in New Hampshire. The YRBS is a paper survey completed in a school setting and overseen by
the New Hampshire Department of Education. The BRFSS is a phone survey conducted by the
New Hampshire Department of Health and Human Services through the University of New
Hampshire Survey Center. National and federal recommendations include the adjustment of
survey questions to better differentiate misuse from abuse. Data are also collected by the New
Hampshire Medical Examiner and the New Hampshire Department of Safety. Currently, existing
state-level data collection such as during emergency room admissions or local police arrests may
not provide adequate specificity for data mining relative to prescription drug misuse, abuse and
diversion. Therefore, it is recommended that existing data collection efforts be expanded and/or
enhanced to better monitor and respond to prescription drug misuse, abuse and diversion.
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SURVEILLANCE & MONITORING
5:7

Provide leadership and oversight in coordinated state-level surveillance,
monitoring and strategic planning

SURVEILLANCE & MONITORING
5:8

Provide reimbursement to health and medical practitioners for Screening,
Brief Intervention and Referral to Treatment (SBIRT)

Although financial resources are scarce for new initiatives, it is recommended that state
government consider means to reimburse health and medical practitioners for SBIRT, explained in
greater detail in the Health & Medical section of this document. Some private insurance plans
include such reimbursement which, when coupled with necessary training and technical
assistance, provides an incentive for prescribers to screen for alcohol or other drug problems,
including prescription drug abuse, and to help patients recognize their own risk of abuse and to
seek specialized care if a substance use disorder is evident. The federal Affordable Care Act may
include reimbursement provisions in 2014 for SBIRT implementation.

RESOURCE DEVELOPMENT
5:9

Expand funding for treatment to increase access for individuals requiring
treatment for prescription drug abuse

With the increase in individuals presenting in state-funded treatment programs for prescription
drug abuse, sufficient capacity to effectively treat substance use disorders, particularly addiction to
opioids, is critical. Treatment provides an opportunity for those struggling with addiction and
dependence to receive effective and culturally sensitive care, to better manage mental and
behavioral health conditions, and to restore their quality of life.
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Government Recommendations

The New Hampshire Governor’s Commission on Alcohol and Drug Abuse Prevention,
Intervention and Treatment provides the structure and process for ongoing leadership and
oversight of state-level surveillance, monitoring and strategic planning relative to prescription
drug abuse. Its relationship to the State Epidemiological Outcome Workgroup for behavioral
health and its prevention, treatment, public education and awareness, and health care task forces
should be leveraged to provide integrated and coordinated surveillance and monitoring of the
population-level data relative to prescription drug abuse as well as of the activities of community
stakeholders and state agencies in support of this Call to Action. The Commission will determine
if its current structure and operations will provide adequate leadership or oversight or if a special
task force will be formed to provide an opportunity for state agencies and partnerships to provide
activity updates relative to this Call to Action. Additionally, the Commission is responsible for the
development and implementation of the state’s five-year strategic plan to prevent, reduce and treat
substance use disorders, currently slated for revision and publication in the fall of 2012. It is
anticipated that prescription drug abuse prevention, intervention and treatment will be prominent
in the revised five-year strategic plan.
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Government Recommendations

Consider specialized or “therapeutic” courts that provide culturally sensitive
5:10 assessments, treatment and recovery opportunities in place of traditional
probation or incarceration
Specialized courts such as drug courts40 and
mental health courts41 exist in several court
systems throughout the state. During the
Prescription Drug Abuse Strategy Summit in
October 2011, it was noted that the legislature
had considered increasing the availability of
drug courts throughout the state but that federal
or other resources would be needed to
implement this strategy. It was also noted that
many intervention programs that in previous
years provided education and treatment
resources in place of traditional probation or
incarceration have closed due to budget
reductions but that leadership within the New
Hampshire Superior Court system is promoting
innovative approaches to alternative sentencing
to better address addiction and mental health
conditions.

List of locations where drug courts and mental
health courts are operational.
Concord:

Drug Court (juvenile offenders only)
Mental Health Court

Nashua:

Drug Court (juvenile offenders)
Mental Health Court

Exeter:

Mental Health Court

Portsmouth: Mental Health Court
Grafton:

Adult Felony Drug Court

Laconia:

Drug Court (juvenile offenders only)

Lebanon:

Mental Health Court

Littleton:

Mental Health Court

Manchester: Mental Health Court

Keene:

Mental Health Court

Rochester:

Mental Health Court

Rockingham: Adult Felony Drug Court
Strafford:

Adult Felony Drug Court

SOURCE: http://www.courts.state.nh.us/drugcourts/index.htm
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RESOURCES
GOVERNMENT POLICY RECOMMENDATIONS
NATIONAL STRATEGY

Center for Lawful Access and Abuse Deterrence (CLAAD)

http://www.claad.org/resources/policy-recommendations
FEDERAL STRATEGY

White House Office of National Drug Control Policy

http://www.whitehouse.gov/ondcp/2011-national-drug-control-strategy
RELATED RESOURCES
Medscape – Substance Abuse & Addiction

http://www.medscape.com/resource/substance-abuse
Bureau of Justice Assistance – Mental Health Courts Program

National Criminal Justice Reference Service – Drug Court Programs

https://www.ncjrs.gov/spotlight/drug_courts/summary.html
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Government Resources

http://www.ojp.gov/BJA/grant/mentalhealth.html
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Special Populations
Special populations affected by prescription drug abuse include military personnel, individuals reentering communities from correctional facilities, and older adults. Below are presented some
data available for each focus population and strategies and resources recommended to address
prescription drug abuse with each population of focus. Other focus populations and specific
recommendations will be reviewed and considered in future Commission work.

MILITARY PERSONNEL
- Between 2002 and 2005, prescription drug abuse among military personnel doubled; and
between 2005 and 2008 almost tripled, while tobacco use and illicit drug use decreased.42
- According to New Hampshire National Guard statistics, during Fiscal Year 2010, there were
39 substance abuse referrals into the Prevention, Treatment, and Outreach (PTO) program and
of those, five were specific to prescription drug abuse.43

Continue implementation of the comprehensive policy within armed forces that prohibits
abusing any substance including prescription medications
Continue required annual training for service members relative to prescription drug abuse,
alcohol use and other drug use.
Continue to disseminate “Harmful Interactions of Prescription Drugs” pamphlets and other
materials relative to the risks and early warning signs of prescription drug abuse
Continue random urinalysis testing to deter and intervene early in potential prescription
drug abuse
Continue to promote the PTO program as a service available to all members of the military
needing help with alcohol abuse or drug use
Through either self-referral or a positive urinalysis, continue to develop and monitor
treatment plans based on a comprehensive assessment of needs
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CORRECTIONS POPULATIONS
During 2010, 1,158 state prison inmates were screened for substance use disorders. Of those
screened 57% reported using or abusing drugs, with 16% of that subset reporting prescription
drug abuse.44
RECOMMENDATIONS

Connect re-entry population with primary care settings and/or health homes, sharing reentry plans with care providers including considerations for alcohol or drug abuse history,
treatment, and recovery plans
Consider special protocols for those working with re-entry populations in relapse prevention
response
Educate re-entry population on risks of prescription drug misuse and abuse within the
context of health promotion and the prevention of relapse and/or recidivism

Special Populations

Educate primary and specialty health and medical professionals in culturally sensitive care
for re-entry populations
Support education of families of re-entry population in risks, warning signs, and resources
available

OLDER ADULTS
According to the National Institute on Drug Abuse, individuals aged 65 years and older comprise
only 13 percent of the population, yet account for more than one-third of total outpatient spending
on prescription medications in the United States.45 Because older populations are more likely to
be prescribed long-term and multiple prescriptions and more likely to experience cognitive
decline, the potential for medication misuse may be heightened. Fixed incomes, interactions with
alcohol consumption, age-related metabolism changes, untreated health conditions, over-thecounter medications, and other contributing factors may increase the risk of harm related to
prescription drug use for older adults.
In New Hampshire, in 2010 deaths related to drug abuse, including prescription drug abuse, were
most prevalent in the 41 to 50 year old age range, followed by the 51-60 year old age range.46
Special attention should be given by prescribers, dispensers, and health educators to the prevention
and early intervention of prescription drug misuse and abuse among older adults.
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RECOMMENDATIONS

Programs unique to New Hampshire, such as the REAP program, provide in-home based
counseling to older adults in mental, emotional and physical health promotion and risk
prevention. These and other programs within primary care may be tapped for increased
education and awareness among older adults who may be a higher risk for prescription
drug misuse and/or abuse.
Health education and patient counseling sensitive to the unique conditions of older adults
should be developed and implemented in a wide range of care settings, including hospitals,
long-term care facilities, assisted living communities, and home- and community-based
support systems.
Problem identification and referral, such as Screening, Brief Intervention and Referral to
Treatment (SBIRT) described in other sections of this report, may provide important
opportunities for physicians, nurse practitioners, social workers, health educators, and
other professionals working with older adults to increase awareness among older adults of
prescription drug dangers and to intervene early if a problem exists.
Special Populations
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Commitments to Action
by State Agency or Stakeholder
This section of the Call to Action presents action plans developed and endorsed by key
stakeholders and member agencies of the Governor’s Commission on Alcohol and Drug Abuse
Prevention, Intervention and Treatment in service to the plan’s goals. The Commission may
establish a task force in 2012 to ensure ongoing implementation of action plans, collaboration in
support of the shared commitments, and monitoring of activities and trend data to determine
successful reductions in prescription drug abuse and its harmful consequences.

Key stakeholder & member agencies committing to specific action in
service to the Call to Action:
Adjutant General of the New Hampshire National Guard
New Hampshire Board of Medicine
New Hampshire Board of Pharmacy
New Hampshire Bureau of Drug & Alcohol Services
New Hampshire Department of Corrections
New Hampshire Department of Education
New Hampshire Department of Safety
New Hampshire Division of Liquor Enforcement
New Hampshire Division of Public Health Services
New Hampshire Medical Society
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New Hampshire Office of the Attorney General
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Adjutant General of the New Hampshire National Guard
The New Hampshire Office of the Adjutant General is committed the following objectives in
service to the state plan to prevent and reduce prescription medication misuse, misdirection and
abuse.

PUBLIC EDUCATION & AWARENESS
Commitment
Action Indicator(s)
6:1 Continue Guard efforts to educate Number of Guard
its soldiers and airmen about
members trained
prescription drug abuse

Time Frame
SFY 2012 &
ongoing

Notes
Existing training requirements for members of
the NH National Guard may be leveraged to
increase knowledge of prescription drug abuse.

6:2 Continue Guard efforts to support
community coalitions and
increase public awareness
through the Guard’s Counter Drug
Task Force

SFY 2012 &
ongoing

Members of the Guard’s Counterdrug Task Force
are currently assigned to the NH Bureau of Drug
and Alcohol Services to support community
coalition development through direct educational
programs, information dissemination, media
messaging, and technical assistance in support of
community engagement in prevention.

Number of community
coalition assistance
requests supported by
the Guard

Commitment
6:3 Continue Guard efforts to support
state-wide Take-Back events to
collect unwanted prescription
drugs

Action Indicator(s)
Data on Guardsupported Rx TakeBack events and
outcomes

Time Frame
SFY 2012 &
ongoing

Notes
The NH National Guard has been supporting
state-wide Take-Back events since the
strategy’s inception in 2010. Three state-wide
events have been held in NH since 2010 in
conjunction with federally designated dates.

SURVEILLANCE & MONITORING
Commitment
Action Indicator(s)
6:4 Continue random drug testing and Data from annual
reporting for prescription drug
drug testing
misuse and abuse among Guard
members

Time Frame
SFY 2012 &
ongoing

Notes
Department of Defense members regularly
submit to random urinalysis testing. It is
anticipated that testing for hydrocodone and
benzodiazepine use will be added to the
standard drug testing panel during federal FY’12.

6:5 Continue Guard efforts to provide Case/analysis
federal, state, and local law
contributions and
enforcement agencies with
outcomes
investigative case and analyst
support

SFY 2012 &
ongoing

The NH National Counterdrug Task Force
currently provides investigative case and
analyst support to numerous law enforcement
agencies operating in the State of NH.

PROBLEM IDENTIFICATION & REFERRAL
Commitment
6:6 Leverage existing counseling
services and Access to Recovery
(ATR) care coordination for Guard
members referred for intervention
or treatment

Action Indicator(s)
Number of Guard members
educated about the referral
process and counseling/
treatment services available
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Time Frame
SFY 2012 &
ongoing

Notes
ATR provides assessments and care
coordination to support treatment
and recovery plans for those Guard
members with a diagnosable
substance use disorder.

Commitments to Action

STORAGE & DISPOSAL
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New Hampshire Office of the Attorney General
The New Hampshire Office of the Attorney General will be responsible for the following
objectives in service to the state plan to prevent and reduce prescription medication misuse,
misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
7:1 Increase the number of trainings
and professional development
opportunities available to and
accessed by law enforcement &
other safety personnel by a
minimum of 2 per year

Action Indicator(s)
Number and participation
of trainings/professional
development offered and
accessed

Time Frame
Notes
SFY 2012 & The AG works in partnership with Policy
ongoing
Standards and Training Unit (PTSU) and other
training organizations.

7:2 Co-develop and provide
collaborative trainings with
multiple stakeholders

Number of trainings
developed, offered and
accessed

SFY 2013 &
ongoing

Topics to include: Enforcing DWI laws
applicable to influence of Rx drugs,
investigating Rx drug forgery cases.

PUBLIC EDUCATION & AWARENESS
Commitment
7:3 Develop and disseminate Legal
Bulletins specific to Rx Drug Abuse
using the existing resources of
the Attorney General’s Office

Action Indicator(s)
Number of
bulletins
developed and
disseminated

Time Frame
Notes
SFY 2013 & This action will be implemented in partnership with
ongoing New Hampshire Intelligence and Analysis Center
(NHIAC), a clearinghouse developed to function as a
focal point of two-way communication amongst all
partners and other state agency information
dissemination channels.

STORAGE & DISPOSAL
Commitment
7:4 Support legislative
rulemaking for
“cooperative action”
relative to periodic
community and/or state Rx
Drug Take-Back events

Action Indicator(s)
Rulemaking
completed and
disseminated

7:5 Provide leadership,
partnership, and support
as needed to encourage
periodic community-level
Rx Take-Back events and
locations

Data on Rx Take-Back
events and outcomes

Time Frame
SFY 2012 &
ongoing

SFY 2012 &
ongoing
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Notes
The formal rulemaking process has been initiated by
the Department of Justice. The rulemaking process
generally takes several months to complete,
requiring a public hearing, a review by attorneys at
the Office of Legislative Services, preparation of fiscal
impact statements by state agencies, and a hearing
before the Legislature’s Joint Legislative Committee
on Administrative Rules.
This action will rely on partnerships with local law
enforcement, federal law enforcement (DEA),
prescribers, pharmacists, and community
organizations and networks.

Commitments to Action

This action requires funding or in-kind
resources including partnerships with training
centers for key constituencies (e.g. health care
professionals, safety & law enforcement,
community coalitions/ networks, public health,
businesses, health educators, and others).

January 2012
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SURVEILLANCE & MONITORING
Action Indicator(s)
Legislation introduced,
passed, enacted

Commitments to Action

Commitment
7:6 Institute prescription drug
monitoring program for
prescribers and pharmacists
through legislation
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Time Frame
Notes
SFY 2012 & The Attorney General’s Office continues to
ongoing
proactively support legislative initiatives to
establish a prescription drug monitoring
program.
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New Hampshire Board of Medicine
The new Hampshire Board of medicine oversees licensing disciplinary action relative to
physicians (M.D. and D.O.) and physician assistants (P.A.) practicing medicine in the State of
New Hampshire. The Board investigates complaints and issues disciplinary action when
appropriate. The Board is also involved in legislative policy and advocacy and the cultivation of
continuing education for licensees. The New Hampshire Board of Medicine is committed to the
following objectives in service to the state plan to prevent and reduce prescription medication
misuse, misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Action Indicator(s)
Number of trainings/
professional development
offered and accessed by
prescribers

Time Frame
Notes
SFY 2012 & Currently working with Boston University
ongoing
Medical School to bring training resources to
NH licensees

8:2 Increase availability and access
to continuing education through
cross-training of prescribers,
specialty care, behavioral
health/ addiction treatment, law
enforcement and others

Number of trainings/
professional development
offered and accessed by
prescribers

SFY 2012 &
ongoing

Collaborative may emerge through
prescription drug task force and will likely
include relationships with the Board of
Pharmacy, the Drug Diversion Unit, the
Medical Society, and the Board of Nursing

PUBLIC EDUCATION & AWARENESS
Commitment
Action Indicator(s)
8:3 Promote public education and awareness Dissemination of
about the role of the Board of Medicine
announcements or
and how to file a complaint
postings

Time Frame
SFY 2012 &
ongoing

Notes
Current website provides
information to the public on how to
file a complaint

SURVEILLANCE & MONITORING
Commitment
8:4 Support legislation relative to
electronic access to patient
prescription drug data

Action Indicator(s)
Testimony and
contributions to
rulemaking
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Time Frame
SFY 2012 &
ongoing

Notes
Board of Medicine has and will testify in
support of prescription drug monitoring
legislation

Commitments to Action

Commitment
8:1 Increase availability of and
access to continuing education
for licensees relative to
prescribing of opioids
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New Hampshire Board of Pharmacy
The NH Board of Pharmacy inspects and investigates consumer and professional complaints
against licensees or registrants. The Board of Pharmacy maintains five full-time staff to regulate
301 in-state pharmacies; 386 out-of-state pharmacies; 2,355 NH-licensed pharmacists; 2,329 NHregistered pharmacy technicians; 994 manufacturers and distributors; and 106 limited drug
distributors. The Board of Pharmacy also conducts inspections of pain clinics in New Hampshire.
The New Hampshire Board of Pharmacy is committed to the following activities in service to the
state plan to prevent and reduce prescription medication misuse, misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
9:1 Increase the number of trainings
and professional development
opportunities accessed by
pharmacists by a minimum of 2
per year

Action Indicator(s)
Number of trainings/
professional development
offered and accessed by
pharmacists

PUBLIC EDUCATION & AWARENESS
Commitment
Action Indicator(s)
9:2 Develop a web portal for pharmacists and Web portal live and
prescribers to share general information accessible to pharmacists
about problems and solutions relative to & prescribers
Rx drug abuse and diversion

Time Frame
SFY 2012 &
ongoing

Notes
This action item will not be
actionable until funding or in-kind
resources become available.

9:3 Update and disseminate the “Pharmacy
Diversion Alert!” document to
pharmacists and pharmacy staff

Manual updated and
disseminated

SFY 2012 &
ongoing

The Board of Pharmacy will explore
funding opportunities to implement
this action.

9:4 Develop and implement a “Pharmacy of
the Month” program to educate
pharmacies in best practices and to
recognize successes in deterring Rx drug
abuse

Program initiated and
operational

SFY 2013 &
ongoing

The Board of Pharmacy will explore
funding opportunities to implement
this activity.

STORAGE & DISPOSAL
Commitment
Action Indicator(s)
9:5 Develop and provide collaborative Number of trainings
trainings with multiple stakeholders developed & accessed
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Time Frame
SFY 2013 &
ongoing

Notes
This action requires funding or in-kind
resources including partnerships with the
state’s Regional Network System or similar
stakeholder representation.

Commitments to Action

Time Frame
Notes
SFY 2012 & Training topics will include Pharmacist-Inongoing
Charge responsibilities, Rx Patrol, fraudulent
scripts, and other drug-seeking scams, Rx drug
disposal/DEA Take-Back events and
opportunities, challenges in pain management,
PharmAssist program (impairment recovery
program for pharmacists), and other trainings
to deter abuse and drug diversion.

January 2012
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SURVEILLANCE & MONITORING
Commitment
Action Indicator(s)
9:6 Increase investigations of pharmacies Increase in
relative to “internal” diversion
investigations
conducted

Time Frame
SFY 2012 &
ongoing

Notes
Funding will be required to increase
investigative resources.

POLICY & LEGISLATION
Action Indicator(s)
Legislation
researched and
introduced

Commitments to Action

Commitment
9:7 Work with the Attorney General’s
office to consider and/or introduce
legislation to limit an individual’s
ability to fill a prescription written
outside of the northeast to one fill
per 10 days
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Time Frame
SFY 2012 &
ongoing

Notes
This action is under consideration due to
pharmacist concerns regarding the
prevalence and pattern of prescriptions
being seen from Florida and other states.
The action may not be necessary if PMP
legislation is passed.
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New Hampshire Bureau of Drug & Alcohol Services
As the federal Single State Authority designee for alcohol and drug abuse efforts, the New
Hampshire Bureau of Drug and Alcohol Services has its primary mission to reduce alcohol and
other drug misuse and its social, health, and behavioral consequences for the citizens of New
Hampshire through public policy and resource development, education, and by supporting
initiatives that ensure the delivery of effective and coordinated prevention, intervention, treatment
and recovery support services. The Bureau carries out its mission through a system of regional
networks focused on community strategies to prevent alcohol and other drug abuse, including the
misuse of prescription drugs, as well as through technical assistance, training, public information,
treatment services and recovery supports to provide an effective continuum of care for
individuals, families and communities.
Through its mission and service array, the Bureau is well poised to implement and promote state-,
community- and provider-level strategies in service to the growing problem of prescription drug
misuse and abuse. The New Hampshire Bureau of Drug and Alcohol Services is committed to the
following objectives in service to the state plan to prevent and reduce prescription medication
misuse, misdirection and abuse.

Commitment
10:1 Increase the number and reach
of training and professional
development relative to
evidence-based approaches to
prescription drug misuse,
including but not limited to
opioid abuse

Action Indicator(s)
Number of trainings
offered and accessed
for prescription drug
abuse prevention,
intervention and
treatment

Time Frame
SFY 2013 &
ongoing

Notes
This action will seek to increasing training
opportunities through existing resources such
as the New Hampshire Training Institute on
Addictive Disorders contractor, the New
England School of Addiction Studies, state
partners, the community college and
university system, federal technical
assistance systems, and other stakeholders.

Documentation of
10:2 Strengthen partnerships and
capacity of state-funded
partnerships and
treatment providers and primary capacity development
care in support of medicationassisted recovery (e.g.
suboxone)

SFY 2013 &
ongoing

This action will leverage systems change
opportunities of the Affordable Care Act (ACA)
to strengthen partnerships between and
capacity of addiction treatment and primary
care.

STORAGE & DISPOSAL
Commitment
10:3 Continue to encourage the
Regional Network System to
facilitate and/or support
community Take-Back events to
collect unwanted Rx drugs

Action Indicator(s)
Data on Regional
Network-supported Rx
Take-Back events and
outcomes
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Time Frame
SFY 2012 &
ongoing

Notes
Efforts are already being undertaken by the
Regional Network System and have been
highlighted during Governor’s Commission
meetings and in this report.

Commitments to Action

PROFESSIONAL DEVELOPMENT & TRAINING

Call to Action: Responding to New Hampshire’s Prescription Drug Epidemic

January 2012

Commitments to Action

SURVEILLANCE & MONITORING
Commitment
10:4 Expand public education and
awareness activities specific to Rx
drug abuse prevention, intervention,
treatment and recovery

Action Indicator(s)
Dissemination of Rx
drug prevention media
and other
communications

Time Frame
SFY 2012 &
ongoing

10:5 Continue the biannual cooperative
administration of the Youth Risk
Behavior Survey (YRBS) with the NH
Department of Education for data
collection relative to youth Rx drug
abuse prevalence, perceived risk,
availability and perceived
wrongness and ensure Rx drug
questions are worded to maximize
understanding of issue and causes

Number and nature of
Rx drug questions on
YRBS

SFY 2013 &
ongoing

10:6 Continue to support the state’s
annual administration of the
Behavioral Risk Factor Surveillance
System (BRFSS) through DHHS Health
Statistics and Data Management for
data collection relative to Rx drug
misuse and abuse

Annual BRFSS Data
outputs relative to Rx
drug abuse
prevalence

Number of schools &
students participating
Data outputs

SEOW data products
10:7 Leverage the work of the State
Epidemiological Outcomes
Workgroup (SEOW) for increased
analysis and indicator
determinations to support the state’s
ongoing surveillance of prescription
drug misuse, abuse, & impacts; make
de-identified prescription data
available to the SEOW for
epidemiological analyses
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Notes
This action will leverage the existing
capacity of Partnership for a Drug Free NH,
the Bureau’s Clearinghouse and Lending
Library, and current communication
conduits such as the Regional Network
System.
This action item relies on shared
resourcing between the NH Bureau of Drug
and Alcohol Services (BDAS) and the NH
Department of Education. Data
dissemination takes place through schools
and the Bureau’s Regional Network System
serving community substance use
prevention priorities

SFY 2012 &
ongoing

In SFY 2009 the Bureau contributed
leadership and funding to add questions to
the BRFSS relative to prescription drug
misuse and abuse to collect data on adult
prevalence and trends. This action is
shared with the NH Department of Public
Health Services.

SFY 2012 &
ongoing

The NH SEOW is making final revisions of
an epidemiological data profile and
recommendations for alcohol and drug
monitoring, including prescription drug
misuse and abuse. It is due for
dissemination in January 2012.
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New Hampshire Department of Corrections
The New Hampshire Department of Corrections will be responsible for the following objectives in
service to the state’s commitments to prevent and reduce prescription drug misuse, misdirection
and abuse among corrections populations re-entering New Hampshire communities.
It is acknowledged here that the New Hampshire Department of Corrections launched a
comprehensive, successful “in-house” response to the growing number of inmates who were
entering correctional facilities with pain and addiction challenges by instituting a pain
management clinic and new prescribing protocols that ensured inmates accessed a multidisciplinary team to treat and manage chronic pain conditions through therapies including physical
therapy, group therapy, diet and exercise rather than a single modality of just medication.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
Action Indicator(s)
11:1 Support increased training Number of trainings
of parole/probation
offered and accessed
officers and applicable
department of corrections
staff regarding
sensitivities of Rx
medication with this
population

Time Frame
SFY 2012 &
ongoing

Notes
This action requires interagency coordination and
shared resources to support curriculum development
and trainers. The action also requires dissemination
channels and policy adaptation to encourage and/or
require attendance at trainings. Topics may include
the myths v. facts of high risk populations, due
diligence of medical proof of Rx need such as x-rays
or physical findings, the role of patient contracts,
and other topics.

SURVEILLANCE & MONITORING
Commitment
Action Indicator(s)
Number of screenings
11:2 Continue screening and
assessment of population and assessments
for risk of prescription
drug abuse upon intake
and re-entry to community

Time Frame
SFY 2012 &
ongoing
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Notes
With Second Change Act funding, the department
has developed Memoranda of Understanding and/or
contracts with community systems of care to support
improved care and support as the population reenters the community.

Commitments to Action

Between 2008 and 2010, the number of hydrocodone-acetaminophen (Vicodin) pills dispensed per
month to New Hampshire inmates fell from 18,400 to 2,700. In addition, for those whose
medications are managed within correctional facilities, the Department ensures that individuals
who rely on prescription medication are prescribed those medications that will be accessible
through Medicaid or other low-cost options, that inmates leaving correctional facilities have a
14-day supply of needed medications, and that, when possible, inmates leaving facilities are
connected with a primary care facility. This strategy ensures that individuals will be able to access
their prescriptions safely and affordably without having to resort to crime or inappropriate
diversion for their medical needs. The activities below further reflect their ongoing commitment to
supporting individuals in their re-entry to communities and traditional community health care and
mental health care settings.
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New Hampshire Department of Education
The New Hampshire Department of Education is committed the following objectives in service to
the state plan to prevent and reduce prescription medication misuse, misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
Action Indicator(s)
Number of trainings
12:1 Increase the number of trainings and
professional development opportunities
offered and accessed
made available to school personnel relative
to prevalence and prevention of Rx drug
misuse and abuse

Time Frame
SFY 2012 &
ongoing

Notes
Training opportunities may be
coordinated with the NH Drug
Diversion Unit and other
state-level partners.

PUBLIC EDUCATION & AWARENESS
Action Indicator(s)
Number and dissemination
of notices relative to Rx
drug abuse originating
from the Department

12:3 Allow department communication
channels to be used to disseminate
information on Rx drug abuse prevention
best practices, Take-Back events,
training opportunities, public
awareness, and related topics

Number and reach
of communications
disseminated using
Department
channels

Time Frame
SFY 2012 &
ongoing

Notes
Collaboration between the
Department of Education and the
Commission’s prevention task
force can support this.

SFY 2012 & This action requires information sources to
ongoing connect to the Department’s communication
channels, such as NH Drug Diversion Unit
presentations to school principals,
Partnership for a Drug Free NH messaging
and materials to schools, local coalition and
regional network messaging to school
personnel and families, etc.

SURVEILLANCE & MONITORING
Commitment
12:4 Continue the biannual administration of
the Youth Risk Behavior Survey (YRBS)
that includes questions relative to Rx
drug abuse prevalence, perceived risk,
availability and perceived wrongness;
ensure Rx drug questions are worded to
maximize understanding of issue and
causes

Action Indicator(s)
Number & nature of Rx
drug questions on
YRBS
Number of schools &
students participating
Data outputs
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Time Frame
SFY 2012 &
ongoing

Notes
This action item relies on shared
resourcing between the NH Department
of Education and the NH Bureau of Drug
and Alcohol Services. Data
dissemination takes place through
schools and the Bureau’s Regional
Network System serving community
substance use prevention priorities.

Commitments to Action

Commitment
12:2 Provide leadership on Rx drug abuse
through Open Letters to principals and
school communities noting importance of
Rx drug awareness and abuse prevention
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RESOURCE DEVELOPMENT
Time Frame
SFY 2013 &
ongoing

Commitments to Action

Commitment
Action Indicator(s)
Resources sought and
12:5 Continue to seek grant
funding and other
acquired
resources to enhance and
expand health promotion
and risk prevention
specific to Rx drug abuse
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Notes
The federal and state fiscal climate has affected
resource opportunities such as the closure of
the federal Safe and Drug Free Schools program),
while ACA reform may provide more resources
opportunities for school-based prevention and
health promotion.
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New Hampshire Department of Safety
The New Hampshire Department of Safety has been a leader in bringing visibility, attention and
resources to the growing epidemic of prescription drug abuse in New Hampshire within the
Department, within the Commission, and within the state at large to coordinate an effective
response to the epidemic. Specifically, the Department launched a Drug Diversion Unit staffed by
a state trooper and pharmacist who specialize in drug diversion investigations across the state and
who commit 50% of their time to training and educating other law enforcement, safety and other
professionals in prescription drug abuse and diversion.
The New Hampshire Department of Safety is committed the following objectives in service to the
state plan to prevent and reduce prescription medication misuse, misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Time Frame
SFY 2012 &
ongoing

Notes
This action will be implemented in
partnership with Policy Standards and
Training Unit, the Drug Diversion Unit, and
other stakeholders. Topics may include
enforcing DWI laws applicable to influence of
Rx drugs, investigating Rx drug forgery cases,
investigating “Doctor Shopping”, and other
relevant topics.

PUBLIC EDUCATION & AWARENESS
Commitment
Action Indicator(s)
Number and
13:2 Develop and disseminate
Intelligence Bulletins specific to dissemination of
Rx drug abuse using the existing bulletins developed
resources of the Intelligence
Analysis Center (IAC)
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Time Frame
Notes
SFY 2012 & In cooperation with the Attorney General’s
ongoing
office, develop an intelligence bulletin strategy
specific to the prescription drug threat to
implement within the law enforcement and
across multiple stakeholder systems such as
pharmacies, hospitals, schools, practitioner
associations, and local government.

Commitments to Action

Commitment
Action Indicator(s)
Number of training
13:1 Increase the number of trainings
and professional development
curricula developed,
opportunities available to and
offered and accessed
accessed by law enforcement and
other safety personnel (e.g. DWI of
Rx Drugs, Rx drug forgery)
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New Hampshire Division of Liquor Enforcement
The New Hampshire Division of Liquor Enforcement is committed the following objectives in
service to the state plan to prevent and reduce prescription medication misuse, misdirection and
abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Action Indicator(s)
Number of law
enforcement trained in
ARIDE annually

Time Frame
SFY 2012 &
ongoing

Notes
ARIDE training helps officers become more
proficient at detecting, apprehending, testing, and
prosecuting impaired drivers and helps prosecutors
familiarize themselves with drugs that impair
driving and proper documentation needed to
prosecute these types of cases.47

14:2 Increase the number of
law enforcement and other
personnel trained as Drug
Recognition Experts (DREs)

Number of law
enforcement and other
personnel trained as
DREs annually

SFY 2012 &
ongoing

Drug Recognition Experts are able to determine if
an individual is under the influence of a prescription
drug and may increase the efficacy of law
enforcement efforts relative to Rx drug abuse.

STORAGE & DISPOSAL
Commitment
14:3 Continue to support local TakeBack events through shared
resources with local law
enforcement

Action Indicator(s)
Data Liquor
Enforcement-supported
Rx Take-Back events and
outcomes
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Time Frame
SFY 2012 &
ongoing

Notes
The Division of Liquor Enforcement has
provided support to several communities
during local Take-Back events and is
committed to continuing that effort.

Commitments to Action

Commitment
14:1 Increase the number of
law enforcement
personnel trained in
Advanced Roadside
Impairment Detection
Enforcement (ARIDE)
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New Hampshire Division of Public Health Services
The New Hampshire Division of Public Health Services is committed to being a responsive,
expert, leadership organization that promotes optimal health and wellbeing for all. As the state
public health department, the Division holds a unique leadership position in the state’s public
health system, setting direction based on science and the public health needs of our residents and
serving as the steward for state and federal funds used to deliver essential public health services.
The Division also holds the authority and accountability to enforce laws to protect the public’s
health.
The state’s public health department oversees the community health center system, including one
center that is involved in a national learning collaborative with the U.S. Centers for Medicaid &
Medicare Services on better integration of patient education, prescribing practices and even an onsite pharmacy. Both this system and maternal and child health services are aware of increasing
prescription drug misuse and abuse among patients and clients and have begun to focus attention
to the problem.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
Action Indicator(s)
Number of trainings
15:1 Support access to and
availability of training and available and
professional development accessed
relative to evidence-based
approaches to prevent
prescription drug misuse
and abuse

Time Frame
SFY 2012 &
ongoing

Notes
This action item will leverage state partner agency
resources for cross-training opportunities for systems
of care overseen by the Division.

These training resources may include those offered by the New
Hampshire Training Institute on Addictive Disorders, the New
Hampshire Department of Safety, and the boards of nursing, medicine,
and pharmacy. Training topics may include patient education,
prescribing practices, when to refer patients to specialized pain care,
and problem identification and referral related to abuse or dependence.

PUBLIC EDUCATION & AWARENESS
Commitment
15:2 Support public education and
awareness activities specific to
Rx drug abuse through existing
dissemination channels and
service delivery systems

Action Indicator(s)
Number and
dissemination of Rx drug
prevention media and
other communications
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Time Frame
Notes
SFY 2012 & The Division will encourage dissemination of
ongoing
existing public education materials within
public health service systems, including patient
education and counseling opportunities.

Commitments to Action

Through its mission and service array, the Division of Public Health Services is well poised to
support and promote state-, community-, and provider-level strategies in service to the growing
problem of prescription drug misuse and abuse and is committed to the following objectives in
service to the state plan to prevent and reduce prescription medication misuse, misdirection and
abuse.
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SURVEILLANCE & MONITORING
Action Indicator(s)

Time Frame

Notes

15:3 Continue to collect and provide access to data Data collection and
relative to prescription drug misuse and
reporting activity
abuse, including the state’s annual
administration of the Behavioral Risk Factor
Surveillance System (BRFSS) and
hospital/emergency room admissions and
discharges through the Division of Health
Statistics and Data Management; as PMP data
become available, work with PMP to support
periodic epidemiological analyses and reports
on data trends and implications

SFY 2012 &
ongoing

The Division is committed to
sustaining key data collection and
monitoring systems to support
prescription drug abuse
surveillance and monitoring.

Commitments to Action

Commitment
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New Hampshire Medical Society
The New Hampshire Medical Society plays an active role in the landscape of prescription drug
abuse prevention through support and leadership relative to legislative policy, professional
development, standards and guidelines, and information dissemination. The Medical Society
maintains a special task force on opioid pain management and provides a comprehensive list of
resources to support practitioners in effective pain management and abuse deterrence. The New
Hampshire Medical Society is committed the following objectives in service to the state plan to
prevent and reduce prescription medication misuse, misdirection and abuse.

PROFESSIONAL DEVELOPMENT & TRAINING
Commitment
Action Indicator(s)
16:1 Continue to provide access to training Number of trainings
and professional development
offered and accessed
relative to prescription drug abuse
and diversion

Time Frame
SFY 2012 &
ongoing

Notes
This action will leverage the cross-training
opportunities with other stakeholders,
including Department of Safety’s Drug
Diversion Unit and Board of Pharmacy.

PUBLIC EDUCATION & AWARENESS
Time Frame
SFY 2012 &
ongoing

Notes
The Medical Society is actively engaged in the
legislative process for current version
of prescription drug monitoring program and
supports data access for those prescribers
not using electronic health records.

Dissemination data
16:3 Utilize existing communication
channels (e.g. list serves, web
resources) to disseminate emerging
data, recommendations, guidelines,
and other information in support of
effective prescribing practices

SFY 2012

Disseminated information may include sample
patient contracts, screening and assessment
tools, guidelines for referral to addiction
treatment, referring to specialty pain care,
prevention of abuse/diversion, patient
information cards, and other topics.
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Commitments to Action

Commitment
Action Indicator(s)
Contributions to
16:2 Support legislation relative to
electronic access to patient Rx drug legislative efforts
data
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APPENDIX A

CONTENT OF EDUCATION PROGRAM
The training for prescribers required by the elements to assure safe use must contain the
following content:
1. General information for safe opioid prescribing
a. Patient selection and assessment
i. Determine goal of therapy
ii. Assessment of the risk of abuse, including history of substance abuse and
serious mental illness
iii. When relevant, determining if patient is opioid tolerant
b. Considerations when prescribing opioids
i. Pharmacokinetics and potential for overdose
ii. Addiction, abuse, and misuse
iii. Intentional abuse by patient or household contacts
iv. Interactions with other medications/substances
c. Managing patients taking opioids
i. Establishing goals for treatment and evaluating pain control
ii. Use of Patient Provider Agreements (PPAs)
iii. Adherence to a treatment plan
iv. Recognizing aberrant behavior
v. Managing adverse events
d. Initiating and modifying dosing of opioids for chronic pain
i. As first opioid
ii. Converting from one opioid to another
1. Converting from immediate-release to extended-release and longacting products
2. Converting from one extended-release and long-acting product to
another
iii. Titrating to effect/tolerability
iv. How to deal with missed doses
e. Maintenance
i. Reassessment over time

ii. Tolerance
f. Monitoring patients for misuse and abuse
i. Utilization of prescription monitoring programs to identify potential abuse
ii. Understanding the role of drug testing
iii. Screening and referral for substance abuse treatment
g. How to discontinue opioid therapy when it is not needed any longer
2. Product Specific Information
a. Pharmacokinetic characteristics
b. Product specific toxicity
c. Requirements for opioid tolerance for certain long-acting and extended-release
products
d. Individual product information modules
i. Fentanyl transdermal system
ii. Hydromorphone ER
iii. Methadone (For the treatment of moderate to severe pain not responsive to
non-narcotic analgesics)
iv. Morphine ER
v. Oxycodone ER
vi. Oxymorphone ER
vii. Buprenorphine (for the management of moderate to severe chronic pain in
patients requiring a continuous, around-the-clock opioid analgesic for an
extended period of time)
viii. New products
3. Patient counseling
a. Information about prescribed opioid
b. How to take opioid properly
i. Adherence to dosing regimen
ii. Risk from breaking, chewing, crushing certain products
c. Reporting adverse effects
d. Concomitant use of other CNS depressants, alcohol, or illegal drugs
e. Discontinuation of opioid

f. Risks associated with sharing, i.e., overdose prevention
g. Proper storage in the household
i. Avoiding accidental exposure
h. Avoiding unsafe exposure by preventing theft and proper disposal
i. Purpose and content of Patient Provider Agreement

PATIENT EDUCATION
Materials to provide to patients as part of patient counseling must include:
1. How to take opioid properly
a. Adherence to dosing regimen
b. Risk from breaking, chewing, crushing certain products
c. Symptoms of overdose
2. Reporting adverse effects
3. Concomitant use of other CNS depressants, alcohol, or illegal drugs
4. Discontinuation of opioid
5. Risks associated with sharing
6. Proper storage in the household
a. Avoiding accidental exposure
7. Avoiding unsafe exposure by preventing theft and proper disposal
8. Purpose and content of Patient Treatment Agreement
9. Links to Web sites with more information about topics 1 through 8

REMS TEMPLATE

Initial REMS Approval: XX/XXXX
Most Recent Modification: XX/XXXX

Application number TRADE NAME (DRUG NAME)
Class of Product as per label
Applicant name
Address
Contact Information
RISK EVALUATION AND MITIGATION STRATEGY (REMS)
I. GOAL:
Reduce serious adverse outcomes resulting from inappropriate prescribing, misuse and abuse of
extended-release (ER) and long-acting (LA) opioids while maintaining patient access to pain
medications. Adverse outcomes of concern include addiction, unintentional overdose, and death.
II. REMS ELEMENTS:
A. Medication Guide or PPI
A Medication Guide will be dispensed with each [drug name] prescription. [Describe in detail
how you will comply with 21 CFR 208.24.]
B. Communication Plan
A communication plan is not required.
C. Elements To Assure Safe Use
1. The sponsor must ensure that training is provided to prescribers who prescribe DRUG. An
outline of the content for this information is described in Appendix A. The training must
include successful completion of a knowledge assessment and proof of successful program
completion. To assure access to DRUG and minimize the burden on the healthcare delivery
system, FDA expects that the training will be conducted by accredited, independent
continuing medical education (CME) providers, to the extent practicable.
2. The sponsor must provide to prescribers information that the prescriber can use to educate
patients in the safe use, storage, and disposal of opioids. An outline of the content for this
information is described in Appendix B.
3. The sponsor must inform prescribers of the existence of the REMS and the need to
successfully complete the necessary training.
D. Implementation Plan

An implementation plan is not required.
E. Timetable for Submission of Assessments
COMPANY will submit REMS Assessments to the FDA no less frequent than 6 months, 12
months, and annually after the REMS is initially approved from the date of approval of the
REMS. To facilitate inclusion of as much information as possible while allowing reasonable
time to prepare the submission, the reporting interval covered by each assessment should
conclude no earlier than 60 days before the submission date for that assessment. COMPANY
will submit each assessment so that it will be received by the FDA on or before the due date.

APPENDIX B

PAIN MANAGEMENT OVERVIEW BY STATE

Action Taken by
STATE State Medical or Osteo Board

Related Statutes,
Rules, and Regulations
Notes/Legislation

AL*

Guidelines for the Use of
Controlled Substances for the
Treatment of Pain

AK

Ala. Admin. Code r. 540-X-4-08.

Prescribing controlled substances,
*Alaska Admin. Code tit. 12, §
40.975.
*AS 11.71 Controlled Substances
*AS 08.80.030(11) PMP
Established AS 17.30.200
Controlled substance Rx
Database

AZ*

Guidelines for the Use of
Controlled Substances for the
Treatment of Chronic Pain
(Approved 09/24/97, Revised
06/03; Spring 2006)
http://www.azmd.gov/StatutesRules/7_policy.aspx

AZ-O*

Guidelines: The Prescribing of
Controlled Substances for the
Treatment of Pain Management
(Approved 01/22/00)
http://www.azdo.gov/StatutesRules/Policy-1.aspx

AR*

* Regulation 2(6)
(Effective 03/13/97, Amended
12/3/98)

CA*

* Guidelines for Prescribing
Controlled Substances for
Intractable Pain
(Adopted in 1994, revised in
2007)
http://www.medbd.ca.gov/pain_
guidelines.html
* Statement by the Board
(Issued 07/94)

Last Updated: 10/29/2010

*The Use of Controlled Substances for the
Treatment of Pain by Advanced Nurse
Practitioners:
http://www.commerce.state.ak.us/occ/pub/nur18
08.pdf (Adopted June 2006)

*Arizona Revised Statutes
section 41-1033
*Ariz. Rev. Stat. Sect. 133412.01
* A.R.S. Controlled Substances,
Title 36, Ch 27- Uniform
Controlled Substances Act
*A.A.C. Title 4, Ch 23, Article 5Board of Pharmacy- Controlled
Substances Rules
*See above
*Advisory Opinion: Use of Controlled
Substances for the treatment of Pain Management
(Nursing Board Guideline 1/2009):
http://www.azbn.gov/documents/advisory_opinion/
AO%20Controlled%20SubstancesUse%20For%20Treatment%20of%20Chronic%20
Pain%20rev%20Jan09.pdf
*Chronic Intractable Pain
Treatment Act, Ark. Code Ann. §
17-95-701 through 17-95-707.
*Arkansas Code Sect. 5-64-201
through 5-64-210
*http://www.healthy.arkansas.go
v/aboutADH/RulesRegs/Controll
edSubstances.pdf
*/http://www.healthy.arkansas.go
v/aboutADH/RulesRegs/controlle
d_substances_list.pdf
* Intractable Pain Treatment Act,
Prescription or administration of
dangerous drugs or prescription
controlled substances for
treatment of pain or condition
causing pain, Cal. Bus. & Prof.
Code § 2241.5.
* Pain Patient’s Bill of Rights,
Findings and declarations; opiate
drugs; pain management, Health
& Safety Code § 124960.

*Board of Pharmacy:
http://www.pharmacy.ca.gov/licensing/prescribe_
dispense.shtml
*Board of Registered Nursing:
http://www.rn.ca.gov/pdfs/regulations/npr-b09.pdf
*California guidelines resulted from a state
sponsored summit in which 120 health care
practitioners, professional and public educators,
representatives from professional schools and
associations and health care consumers met to

1

Action Taken by
STATE State Medical or Osteo Board

Related Statutes,
Rules, and Regulations
*Uniform Controlled Substances
Act: Cal. Health & Safety Code,
Div. 10 Sec 11000

CA-O
CO*

CT*

DE*

DC

See CA above
(1) Guidelines for Prescribing
Controlled Substances for
Intractable Pain
(Adopted 05/16/96)
(2) Model Policy for the use of
Controlled Substances for the
Treatment of Pain (Revised
11/18/04)
http://www.colorado.gov/cs/Sat
ellite?blobcol=urldata&blobhea
der=application%2Fpdf&blobhe
adername1=ContentDisposition&blobheadername2=
MDTType&blobheadervalue1=inline
%3B+filename%3D47%2F586
%2Fguidelines+for+prescribing
+controlled+substances.pdf&blo
bheadervalue2=abinary%3B+ch
arset%3DUTF8&blobkey=id&blobtable=Mun
goBlobs&blobwhere=12516163
62183&ssbinary=true
Statement on the Use of
Controlled Substances for the
Treatment of Pain
(Adopted 02/15/05; Revised
06/2005)
http://www.ct.gov/dph/lib/dph/p
hho/medical_board/guidelines/st
atementoftheconnecticutmedical
examiningboardrevised62005.pd
f
Model Policy for the use of
Controlled Substances for the
Treatment of Pain
(Adopted 06/02/09)
http://dpr.delaware.gov/boards/
medicalpractice/adoptedpainpoli
cy.shtml

Standards for the Use of
Controlled Substances for the
Treatment of Pain
http://hpla.doh.dc.gov/hpla/fram
es.asp?doc=/hpla/lib/hpla/medic
ine/updated_regs_6_30_2008.pd
f

Last Updated: 10/29/2010

Notes/Legislation
recommend solutions to legal, professional, and
educational barriers to effective pain
management. A report, Summit on Effective Pain
Management: Removing Impediments to
Appropriate Prescribing, was issued by the
Governor of California

* Adopted FSMB Model Policy
*Controlled Substances Act:
Colo. Rev. Stat. Sect 18-18-308
*Intractable Pain Treatment Act:
12-36-117

* Adopted FSMB Model Policy

*Nursing Board Policy Statement also adopted
FSMB Model Policy (12/06):
http://aspi.wisc.edu/documents/pdf/CTnursepolic
y.pdf

* Adopted FSMB Model Policy
*16 Del. C., Ch 47 Sect 47014701-4796 (DE Office of
Controlled Substances)
*Controlled Substances Rules:
http://regulations.delaware.gov/A
dminCode/title24/Uniform%20C
ontrolled%20Substances%20Act
%20Regulations.pdf
D.C. Mun. Regs. tit. 17, § 4614.
*Pharmaceutical Control Division/Health
Regulation & Licensing Administration

2

Action Taken by
STATE State Medical or Osteo Board

Related Statutes,
Rules, and Regulations
Notes/Legislation

FL*

* Management of Pain Using
Dangerous Drugs and
Controlled Substances-General
Practice Guideline
(Adopted 10/25/96)
* Joint Statement on Pain
Management-Florida Boards of
Medicine, Nursing, Osteopathic
Medicine and Pharmacy
(Approved 09/19/05)

FL-O*

*Standards for the Use of
Controlled Substances for
Treatment of Pain
(Adopted 03/9/00)
* Joint Statement on Pain
Management-Florida Boards of
Medicine, Nursing, Osteopathic
Medicine and Pharmacy
(Approved 09/19/05)
* Guidelines for the Use of
Controlled Substances for
Treatment of Pain: Ten Steps
(Adopted 01/11/08)
None found
*Pain Management Guidelines
(Adopted 01/06, modified
03/08/06)
*Guidelines: Prescribing
Opioids for Chronic Pain
(Effective 03/95)
* Model Policy for the use of
Controlled Substances for the
Treatment of Pain
(Adopted 08/05)

GA

Guam
HI *

ID*

IL

IN
IA*

* Standards of practice-appropriate pain management
* Joint Statement on Pain by the
Iowa Boards of Medicine,
Nursing, Pharmacy and
Physician Assistants

KS*

* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
(Adopted 10/17/98)

Last Updated: 10/29/2010

* Fla. Stat. § 458.326.
* Pain Management and
Palliative Care, Fla. Stat. §
765.1103.
* Fla. Admin. Code. Ann. r.
64B8-9 Standards of Practice for
Medical Doctors:
https://www.flrules.org/gateway/
RuleNo.asp?title=STANDARDS
OF PRACTICE FOR MEDICAL
DOCTORS&ID=64B8-9.013
(effective 11/28/10)
*Pain Clinics (effective 10/1/10):
http://www.doh.state.fl.us/mqa/m
edical/info_SB2272.pdf (was SB
2272; SB2722 CH 2010-211)
* Fla. Admin. Code. Ann. r.
64B15-14.005.

*GA Ann. Tit. 16, Ch 13
*GA State Board of Pharmacy
Rule 480-22

* Adopted FSMB Model Policy

* Adopted FSMB Model Policy
* Uniform Controlled Substances
Act: Title 37, Ch 27

*Controlled Substances Act:
Admin. Code Title 77, Ch VI,
Part 1650
*Title 35 Article 48: Controlled
Substances
* Iowa Admin. Code r. 65313.2(148,272C).

* Adopted FSMB Model Policy
* Legislative findings on pain
treatment, Kan. Stat. Ann § 654976.

3

Action Taken by
STATE State Medical or Osteo Board

Related Statutes,
Rules, and Regulations
Notes/Legislation

KY*

LA*

ME*

ME-O*

MD*

MA*

http://www.ksbha.org/misc/pain
mgmt.html
* Joint Policy Statement of the
Kansas Boards of Healing Arts,
Nursing and Pharmacy on the
Use of Controlled Substances
for the Treatment of Pain
(Effective 07/17/02)
http://www.ksbha.org/misc/joint
painmgmt.html
* Model Guidelines for the Use
of Controlled Substances in Pain
Treatment
(Adopted 03/22/01, Revised
09/18/03; 10-10-08)
http://kbml.ky.gov/NR/rdonlyre
s/B0538843-6E6D-48B2-B67BA5D0E6C37C77/0/BoardOpini
onUseofControlledSubstances.p
df
* Guidelines for Prescribing
Controlled Substances (Adopted
06/20/96)
*Medications used in the
Treatment of Non-CancerRelated Chronic or Intractable
Pain
*Opinion: Interventional Pain
Management (06/2006):
http://www.lsbme.louisiana.gov/
Statements%20of%20Position/I
nterventional%20Pain%20Mana
gement.pdf
*Use of Controlled Substances
for Treatment of Pain
(Effective 06/13/2010)

*Persons suffering from pain; use
of controlled substances for pain
treatment, Kan. Stat. Ann § 654977 and 4101
* K.A.R. 68-20-1

*KY Controlled Substances Act: *Operates KY All Schedule Prescription
*KRS 218A; and KRS 217- Food Electronic Reporting (KASPER) System
Drug and Cosmetic Act

*La. Admin Code. tit. 46, pt.
XLV, §§ 6915; 6917; 6919; 6921;
6923

* Adopted FSMB Model Policy
(added section on end of life
pain therapy)
*Code Me. R 02-373 Ch. 11, § 1
through 3
*32 MRSA §3269(3), (7)

* Use of Controlled Substances * Adopted FSMB Model Policy
for Treatment of Pain (Effective (added section on end of life
06/13/2010)
pain therapy)
*Code Me. R 02-383 Ch. 11, § 1
through 3.
*32 MRSA §2562
*Guidelines for Prescribing
Source: Maryland BPQA
Controlled Drugs
Newsletter, Vol. 4, num. 1, pp. 1(Adopted 03/96)
3, Mar. 1996 (Similar to FSMB)
* Prescribing Practices, Policy
* Adopted FSMB Model Policy
and Guidelines
*http://www.massmedboard.org/r
(Adopted 05/3/89, Amended
egs/pdf/Prescribing_Guidelines_F
5/19/2010)
INAL_2010.pdf
* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain

Last Updated: 10/29/2010
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Related Statutes,
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Notes/Legislation

MI*

MI-O*

MN*

MS

MO*

MT

(Adopted 12/12/01)
Guidelines for the Use of
Controlled Substances for the
Treatment of Pain (Adopted in
2003)

Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
(Adopted in 2003)
*Endorsed Model Policy for the
Appropriate Use of Controlled
Substances for the Treatment of
Pain
*Model Guidelines for the Use
of Controlled Substances for the
Treatment of Pain (Adopted Fall
2000)
* Joint Statement on Pain
Management (Adopted 09/04)
*Present a Chronic Pain
Management Seminar 10/28/10
*Article: 12/31/2009
http://www.state.mn.us/mn/exter
nalDocs/BMP/New_Article_on_
Pain_Management_0201100342
48_monograph_dec_07_final.pd
f
* Use of Controlled Substances
for Chronic (Non-Terminal)
Pain (Effective 04/18/99)
*Pain, Pain Management and
Mississippi State Board of
Medical Licensure Scrutiny
(Effective Fall 1997)
MSBML Newsletter - Fall 1997
- Vol.1, No.10
*Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
(Effective 11/01/01)
http://pr.mo.gov/boards/healinga
rts/CSGUIDE.pdf
*A Guide:
http://pr.mo.gov/boards/healinga
rts/TaskforceGuideline.pdf (Jan
2009 Taskforce)
* Statement on the use of
Controlled Substances in the
Treatment of Intractable Pain
(Adopted 03/15/96)
*Joint Board Policy Statement
of the prescribing and filling of

Last Updated: 10/29/2010

* Adopted FSMB Model Policy
*Mich. Comp.Laws Sect
333.16204a (advisory cmte on
pain and symptom management)
*Intractable Pain: Mich. Comp.
Laws sect 333.16204b-c
*To develop a booklet on
intractable pain 333.16204d
* Adopted FSMB Model Policy

* Adopted FSMB Model Policy
* Intractable Pain, Minn. Stat. §
152.125.

* Code Miss. Rules 50 013 001.
Ch. 25 Sec. 6.

* Adopted FSMB Model Policy
* Intractable Pain Treatment
Act—definitions, Mo. Rev. Stat.
§ 334.105.
* Prescription, administration,
and dispensing controlled
substances for intractable pain-therapeutic use--drug
dependency, Mo. Rev. Stat. §
334.106.
* Adopted FSMB Model Policy
(adopted 1/23/09; rev. 3/27/09)
*MT Medical Assoc. Bulletin,
Vol. 51, num. 1, March 15, 1996,
pp3-4

*JOINT STATEMENT OF THE MISSOURI
STATE BOARD OF REGISTRATION FOR
THE HEALING ARTS AND THE MISSOURI
BOARD OF PHARMACY ON INTERNET
PRESCRIBING AND DISPENSING:
http://pr.mo.gov/boards/healingarts/PharmInterne
tPrescribeDispense.pdf
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NE*

NV*

NV-O
NH*

NJ

NM*

NM-O

NY

NC*

controlled substances in the
treatment of chronic pain
(Adopted 07/27/02)
* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
(Effective 02/7/99)
(2) Model Policy for the use of
Controlled Substances for the
Treatment of Pain (Adopted
06/05)
* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
(Adopted 07/19/00) NAC
630.187
* Model Policy for the Use of
Controlled Substances for the
Treatment of Pain

* Guidelines for the Use of
Controlled Substances in the
Management of Chronic Pain
(Amended 03/08/09)
* Limitations on prescribing,
administering or dispensing of
controlled substances; special
exceptions for management of
pain N.J. Admin. Code 13:357.6.
* Guidelines on Prescribing for
Pain (Effective 04/05/99)
* Management of Chronic Pain
with Controlled Substances
(Effective 01/20/03)
* Joint Statement on the
Management of Chronic Pain
(Adopted 05/2005)
*Joint Statement on the
Management of Chronic Pain
(Adopted 08/2005)
*Policy Statement for the Use of
Controlled Substances for the
Treatment of Pain (Effective
03/00)
* Management of Chronic NonMalignant Pain Statement
(Adopted 09/13/96)
*End-Of-Life Responsibilities
and Palliative Care Statement
(Adopted 10/21/99)
* Joint Statement on Pain
Management and End-Of-Life

Last Updated: 10/29/2010

* Adopted FSMB Model Policy
* Ch. 71. Public Health &
Welfare, Art. 24., (D) Drugs, Pain
Management, Neb. Rev. Stat. §§
71-2418 through 71-2420.

* Adopted FSMB Model Policy
* Adoption by reference, Nev.
Admin. Code ch. 630, s 187.
* Prescribing or administering
certain controlled substances for
treatment of intractable pain not
grounds for disciplinary action,
Nev. Rev. Stat. § 630.3066.
* Exemption from grounds:
"Intractable pain" defined, Nev.
Rev. Stat. § 630:255.
*NRS 633.521
* Adopted FSMB Model Policy
* N.H. Admin. R. Ann. Med
501.02.

* Pain Relief Act, N.M. Stat.
Ann. §§ 24-2D-1 through 24-2D6.
* N.M. Admin. Code tit. 16, §
10.14.
http://www.nmmb.state.nm.us/pol
iciesandpositions.html

http://www.health.state.ny.us/pub
lications/4179.pdf

* Adopted FSMB Model Policy
*North Carolina Board of
Medical Examiners
Source: Forum, num. 4,
December, 1996
*http://www.ncmedboard.org/pos
ition_statements/by_tag/tag/pain/
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ND

NMI
OH

OK*

OK-O
OR

PA*

PA-O
PR
RI*

Care (Adopted 10/21/99)
* Policy for the Use of
Controlled Substances for the
Treatment of Pain (Adopted
07/05)
*Controlled Substances for Care
and Treatment (Effective
08/1/95, Revised 03/14/05)
None found
*Position Paper-Scheduled Drug
Therapy Including Narcotics for
Chronic Benign Pain (Effective
06/14/95-Revised 08/14/96)

* Guidelines for Prescribing
Controlled Substances for
Intractable Pain
(Effective in 1995)
* Use of Controlled Substances
for the Treatment of Pain
(Effective 03/10/05)

* Statement of PhilosophyAppropriate Prescribing of
Controlled Substances
(Adopted 05/20/91)
* Statement of Philosophy-Pain
Management in Acute
Conditions and in Terminal
Illness (Adopted 04/95)
* Current Statement of
Philosophy on Pain
Management
(Adopted 04/16/99, Revised
07/9/04)
* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain (Effective
10/20/98) State Board of
Medicine bulletin, Winter
1998/99, pp. 4-5
None found
* Guidelines for Long Term
Pain Management
(Adopted 05/10/95-Referenced
CA policy) Newsletter of the
Rhode Island Board of Medical

Last Updated: 10/29/2010

*N.D. Cent. Code §§ 19-03.3-01
through 19-03.3-06.

*ND Board of Nursing Statement on Pain:
https://www.ndbon.org//opinions/role%20of%20
nurse%20in%20pain%20mgmt.asp

* Authority to treat intractable
pain with dangerous drugs, Ohio
Rev. Code Ann. § 4731.052;
Continuing medical education
course on treating intractable
pain, Ohio Rev. Code Ann. §
4731.283
* Intractable Pain Treatment,
Ohio Admin. Code §§ 4731-2101 to 4731-21-06.
* Adopted FSMB Model Policy
* Appropriate pain management-high dosages of controlled
dangerous drugs, Okla. Stat. tit.
63, § 2-551.
* Use of controlled substances for
the management of chronic pain,
Okla. Admin. Code § 435:10-711.
*OAC 510:5-9-1 Through 5-9-3
* Pain Treatment Act, Or. Rev.
*The Pain Management Commission is
Stat. Ann. §§ 677.470 through
established within the Department of Human
677.480.
Services (SB885 2001)
* Written Notice Disclosing the
Material Risks Associated with
Prescribed or Administered
Controlled Substances for the
Treatment of "Intractable Pain,"
Or. Admin. R §§ 847-015-0030.

* Adopted FSMB Model Policy
* Prescribing, administering and
dispensing controlled substances,
Pa. Code tit. 49, § 16.92.

* Intractable Pain Treatment, R. I.
Gen. Laws §§ 5-37.4-1 through
5-37.4-3.
*2002, Pain Assessment Act: RI
Pub Laws 331
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Licensure and Discipline,
Summer 1995, p.2

SC*

SD*

TN*

TN-O*

*Guidelines for the Use of
Controlled Substances for the
Treatment of Pain (Adopted
02/99)
Guidelines for the Use of
Controlled Substances for the
Treatment of Pain (Adopted
01/99)
*Management of Prescribing
with Emphasis on Addictive or
Dependence Producing Drugs
Statement (Approved 09/19/95)
*9 Step Process Similar to NC
and MN

Related Statutes,
Rules, and Regulations
Notes/Legislation
*Practitioners Immunity from
disciplinary action for
prescription for pain management
RI Pub. Laws 046
* Adopted FSMB Model Policy *Joint Position Statement on Pain Management
for The South Carolina Board of Nursing and
The South Carolina Board of Pharmacy
* Adopted FSMB Model Policy

* Authority of Physician to
Prescribe for the Treatment of
Pain, Tenn. Comp. R. & Regs.
0880-2-.14(6).
* Intractable Pain Treatment Act,
Tenn. Code Ann. §§ 63-6-1101
through 63-6-1111. (2001 Tenn.
Pub. Acts 327)

Guidelines for the Use of
Controlled Substances for the
Treatment of Pain
*Pain Control Statement
(Adopted Spring/Summer 1993)
Newsletter, Volume 15, num. 1,
Spring/Summer 1993, p.1
* Board Rules, Administrative
Code, Title 22, Part 9, Chapter
170, Pain Management
(Effective 01/04/07)

Tenn. Comp. R. & Regs. 1050-2.13(5).
* Intractable Pain Treatment Act,
Tex. Occupations Code §§
107.001 through 107.201.
* Pain Management, Tex. Admin.
Code tit. 22, §§ 170.1 - 170.3.
* Texas Controlled Substances
Act, Chapter 481 of the Texas
Health and Safety Code, relating
to the prescribing and dispensing
of controlled substances

*Effective September 1, 2010, a pain
management clinic may not operate in Texas
without obtaining a certificate from the Texas
Medical Board (TMB)

UT*

* Guidelines for the Use of
Controlled Substances for the
Treatment of Pain (Effective
02/10/99)
* Prescribing Controlled
Substances for Cancer Pain:
Position Paper (Adopted
04/10/92)

* Adopted FSMB Model Policy
* Unprofessional Conduct, Utah
Admin. Code r.156-1-502.(6).

* HB 28: active prescribing practitioners are
required to register with the Controlled Substance
Database by September 30, 2010
http://www.commerce.utah.gov/releases/10-1026_opl-csd-growth.pdf
*HB 89 License for Controlled Substances
Amendments (Rep Morley)
- modifies the Controlled Substance Precursor
Act; provides for the Division of Occupational
and Professional Licensing to issue a controlled
substance precursor license, which combines the
current controlled substance precursor purchaser
and controlled substance distributor licenses.

UT-O
VT*

See UT above
*Report of the Prescribing
Practices Committee (Adopted
06/05/96)
* Policy for the Use of
Controlled Substances for the
Treatment of Pain (Adopted

TX*

Last Updated: 10/29/2010

* Adopted FSMB Model Policy
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VT-O
VA*

VI
WA

12/07/05)
See VT above
* Guidelines for the Use of
Opioids in the Management of
Chronic, Noncancer Pain
(Adopted 02/05/98)
* Model Policy for the Use of
Controlled Substances for the
Treatment of Pain (Adopted
06/24/04)
None found
* Guidelines for Management of
Pain (Approved 04/18/96)

Last Updated: 10/29/2010

* Adopted FSMB Model Policy
*Prescription in excess of
recommended dosage in certain
cases, Va. Code Ann. §§ 54.13408.1, § 54.1-2971.01.

[* Regulation of Manufacture,
Distribution and Dispensing of
Controlled Substances,
Prescriptions, Wash. Rev. Code §
69-50-308(g).
* Pain Management, Wash.
Admin. Code §§ 246-919-800
through 830.]

**A new section is added to chapter 18.57A
RCW 35 to read as follows:
36 (1) By June 30, 2011, the board shall repeal its
rules on pain
37 management, WAC 246-854-120 through
246-854-150.
ESHB 2876.PL p. 4
1 (2) By June 30, 2011, the board shall adopt new
rules on chronic,
2 noncancer pain management that contain the
following elements:
3 (a)(i) Dosing criteria, including:
4 (A) A dosage amount that must not be
exceeded unless an osteopathic
5 physician's assistant first consults with a
practitioner specializing
6 in pain management; and
7 (B) Exigent or special circumstances under
which the dosage amount
8 may be exceeded without consultation with a
practitioner specializing
9 in pain management.
10 (ii) The rules regarding consultation with a
practitioner
11 specializing in pain management must, to the
extent practicable, take
12 into account:
13 (A) Circumstances under which repeated
consultations would not be
14 necessary or appropriate for a patient
undergoing a stable, ongoing
15 course of treatment for pain management;
16 (B) Minimum training and experience that is
sufficient to exempt an
17 osteopathic physician's assistant from the
specialty consultation
18 requirement;
19 (C) Methods for enhancing the availability of
consultations;
20 (D) Allowing the efficient use of resources;
and
21 (E) Minimizing the burden on practitioners
and patients.
22 (b) Guidance on when to seek specialty
consultation and ways in
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Related Statutes,
Rules, and Regulations
Notes/Legislation
23 which electronic specialty consultations may
be sought;
24 (c) Guidance on tracking clinical progress by
using assessment
25 tools focusing on pain interference, physical
function, and overall
26 risk for poor outcome; and
27 (d) Guidance on tracking the use of opioids,
particularly in the
28 emergency department.
29 (3) The board shall consult with the agency
medical directors'
30 group, the department of health, the
University of Washington, and the
31 largest association of osteopathic physician's
assistants in the state.
32 (4) The rules adopted under this section do not
apply:
33 (a) To the provision of palliative, hospice, or
other end-of-life
34 care; or
35 (b) To the management of acute pain caused
by an injury or a
36 surgical procedure.

WA-O
WV*

* Position Statement on the Use
of Opioids for the Treatment of
Chronic Non-Malignant Pain
(Adopted 07/14/97)
* Model Policy for the Use of
Controlled Substances for the
Treatment of Pain (Adopted
01/10/05)
*Rational prescribing practices
or how to avoid board scrutiny,
92 West Virginia Medical
Journal 256 (September/October
1996)
*Joint Policy Statement on Pain
Management at the End of Life
(Approved 03/12/01)
WV-O* *Model Policy for the Use of
Controlled Substances for the
Treatment of Pain
(Adopted 11/04/04)
*West Virginia Boards of
Examiners for Registered
Nurses, Medicine, Osteopathy,
and Pharmacy
Joint Policy Statement on Pain
Management at the End of Life
Approved: March 12, 2001
WI*
* Model Policy for the Use of
Controlled Substances for the
Treatment of Pain

Last Updated: 10/29/2010

* Adopted FSMB Model Policy
* Management of Intractable
Pain, W. Va. Code §§ 30-3A-1
through 30-3A-4.

* Adopted FSMB Model Policy

* Adopted FSMB Model Policy
(2) Wis. Stat. §§ 961.001 and
961.38.
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WY

*Policy Number 40-01
adopting Wyoming Health Care
Licensing Boards’ Uniform
Policy for the Use of Controlled
Substances in the Treatment of
Pain(Issued 02/13/09)

*35-25-206. Pain Management
creating a pain management
advisory committee (2007)

For informational purposes only: This document is not intended as a comprehensive statement of the law on this topic, nor to be relied upon as authoritative.
Non-cited laws, regulation, and/or policy could impact analysis on a case-by-case or state-by-state basis. All information should be verified independently.

* by the states abbrv. indicates policy same or similar to FSMB policy.
 Visit http://www.medsch.wisc.edu/painpolicy/index.htm for guidelines and statutes by state on the Pain and
Policy Studies Group website at the University of Wisconsin
 Newfoundland Medical Council adopted FSMB Model Guidelines in 2000
 National Association of State Controlled Substances Authorities endorsed FSMB Model Guidelines 10/29/1999
 National Association of State Controlled Substances Authorities endorsed FSMB Model Policy 10/23/2004

Last Updated: 10/29/2010
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APPENDIX C

170 Middle Street
Lancaster, NH 03584
Phone: 603-788-2521
Fax: 603-788-5092

PO Box 240
Whitefield, NH 03598
Phone: 603-837-9005
Fax: 603-788-5072

47 Church Street
Groveton, NH 03582
Phone: 603-636-1101
Fax: 603-788-5059

Informed Consent and Controlled Substance Agreement
A. Patient Consent
I, _______________________________________, understand and agree to follow
Please print your full name Date of Birth
the policies regarding the use of opioids, narcotics, or other controlled
substances for management of chronic conditions. I understand that
______________________________ is under no obligation to prescribe these
Provider’s Name
medications for me. I also understand that breaking the terms within this
agreement may lead to its termination and/or my dismissal from treatment. I have
tried other medical treatments which have not worked to control my condition.
I also understand that these medications are not expected to entirely eliminate
all of my symptoms, but are intended to help me to improve my quality of life. This
is a decision that I have made after fully discussing the risks, benefits, as well as
alternatives to this treatment with my provider.
B. Risks of Medications
I understand that treatment of my condition with medications does have risks
including but not limited to:
 Physical symptoms -constipation; sleepiness or drowsiness; problems with
coordination or balance that may make it unsafe to operate dangerous
equipment or vehicles, agitation, confusion; decreased appetite; problems
urinating; sexual difficulties.
 Physical dependence – meaning that abrupt discontinuation of the drug may
lead to withdrawal symptoms including: runny nose, diarrhea, abdominal
cramping, “goose flesh,” and/or anxiety. I understand that this may be
uncomfortable but not life-threatening and the worse symptoms generally
resolve within 72 hours.
 Psychological dependence – meaning it is possible that discontinuation of
the drug may cause me to miss it or crave it.
 Known or unknown risk to unborn and nursing children.
Contraception is highly recommended.
_________(initials)
C. Your responsibilities and Conditions of the Agreement:
1. I will inform my Provider of any history of problems with substance abuse,
illegal drugs, or drug dependence.
2. I am currently not involved in the sale, illegal possession, diversion or
transport of controlled substances, nor do I live with or associate with
individuals who do. If a weeks medical center provider has reason to believe I
am diverting my medication(s) covered under this contract, it will be
immediately reported to the appropriate law enforcement agency. Information
provided to law enforcement will include my name, date of birth and last
known address.
3. I will immediately contact the clinic if any severe depression, thoughts of
suicide or harming others occurs.
4. I agree to obtain controlled medications only from my provider. I will notify
my provider with 24 hours of any prescriptions for controlled substances
provided by other providers.
www.weeksmedical.org (page 1 of 3)
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Lancaster, NH 03584
Phone: 603-788-2521
Fax: 603-788-5092

PO Box 240
Whitefield, NH 03598
Phone: 603-837-9005
Fax: 603-788-5072

47 Church Street
Groveton, NH 03582
Phone: 603-636-1101
Fax: 603-788-5059

5. I will use only_______________________________for filling my prescriptions.
Name of Pharmacy
6. I will not change the amount or the frequency of these medications without
prior approval of my provider.
7. I will inform my Provider of any alcohol consumption because it may interact
with the medications prescribed.
8. I give permission to my Provider or their agents to communicate with Emergency
Departments, Pharmacists, Law Enforcement, other providers, dentists or others
as required to ensure my safety during my treatment with controlled substances.
9. If recommended by my Provider, I will participate in all health care
consultations, referrals, evaluations, or alternative treatment modalities to
include psychiatric evaluation, acupuncturist, physical therapy, occupational
therapy, or other treatment methods prescribed by my provider. I will keep all
scheduled appointments and understand that this agreement may be cancelled if I
miss any appointments with my Provider or any recommended treatments.
10. I understand and consent to have unannounced blood screen, urine tests, or
pill counts in order to assess my compliance with my medical regimen and identify
any other medications or substances that I am taking. If notified, I will have 24
hours to comply with the request. I am aware there are charges for these
services, and I will be responsible for them.
11. I will keep my Provider informed of current contact information including
phone number and address.
12. I understand, in general, allowances will not be made for lost, stolen, or
damaged drugs or prescriptions.
13. I will not call the clinic requesting refills prior to the date due.
14. Requests for refills must be made before 12 noon, 72 hours prior to
expiration of the prescription during normal office hours Monday- Friday
15. The Emergency Department will not be used for controlled substance
medication refills and generally, if presenting to the Emergency Department for
refills, the request will be denied
_____(initials)
D. Confirmation and Understanding
1. I understand that, in general, my controlled medications may be discontinued if
any of the following occur:
 Provider finds that the medications are not effective
 I give, sell, or misuse drugs
 I obtain controlled substances from other sources
 Test results indicate the improper use of my prescribed medications
or the use of illegal drugs
 I violate any of the terms of this consent agreement.
2. I agree that a copy of this document may be given to my primary care provider,
Emergency Departments, my pharmacist, or other health care providers involved
in my treatment.
3. I agree that my Provider or their agents may contact law enforcement if there
is suspicion of my committing illegal activities but not limited to selling drugs
and/or sharing my medications.

www.weeksmedical.org (page 2 of 3)
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I have read this document and understand it. I consent to the use of medications
to help control my symptoms, and I understand that my treatment with these
medications will be carried out in accordance with the condition stated above.

Patient’s Signature

Date

Witness

Date

E. Providers Certification
I certify that the above named patient or responsible individual has received a
careful explanation of the treatment to be provided including the risks and
benefits to be expected. I have disclosed alternative methods of treatment
that might be appropriate for this patient. I have offered to answer any
questions by the patient and/or responsible individual regarding this
treatment.

Provider’s Signature

Date

PROCEDURE FOR OBTAINING CONTROLLED SUBSTANCE PRESCRIPTIONS
1) A photo ID shall be presented to the receptionist to verify identity.
2) If someone other than you will be picking up the prescriptions, that person
must Present a photo id and sign as indicated in #3 below.
3) A signature will be obtained when picking up controlled substance
prescriptions
4) If there is no photo ID presented, the prescription for controlled
substances will not be given out under ANY circumstances.

By signing you understand the procedure for obtaining the prescriptions for
controlled substances. Compliance is part of your contract.

Patient’s Printed Name

Patient’s Signature

www.weeksmedical.org (page 3 of 3)
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_____________________________________________________________
February 24, 2009
«FirstName» «LastName»
«MailingAddress1»
«MailingAddress2»
Dear «FirstName»,

It has come to our attention that you have broken your pain agreement with
your provider at Weeks Medical Center. The section of the agreement that
was broken is:
Prescriptions for controlled substances not filled at the designated
pharmacy
Prescriptions for controlled substances obtained from multiple providers
Prescriptions for controlled substances filled at multiple pharmacies.
Recurrent requests to fill controlled substances before they were
due to be refilled.
Failure to follow up as agreed.
Failed urine drug screening test.
Failed pill count.
Failure to take controlled substances as directed as confirmed by a
negative urine test.
Notification by authorities of use, sale, diversion, or transport of illegally
obtained controlled substances (narcotics or illegal drugs).
Consequently,
You will no longer be able to obtain care at Weeks Medical Center
Physician Offices. If we are treating you for other medical problems not
related to pain management, we will continue to provide services for these
conditions for the next 30 days to give you time to establish care with another
provider. Upon notice we will forward your records to your new provider at no
charge. No additional narcotics will be prescribed to you. In the event of an
emergency, you should seek care at the nearest emergency room.
Weeks Medical Center providers will not prescribe controlled
substances to you, but your current PCP is willing to continue to treat you
for your other healthcare issues.
Your current controlled substance prescription will not be refilled.
any questions regarding this letter, please call the office.
Sincerely,
www.weeksmedical.org
revised 022511

If you have

APPENDIX E

Prescription Drug Abuse
NIDAMED Patient Resources Series

To download this and other flyers in this series, visit http://www.drugabuse.gov/nidamed.

What You Need To Know

Treatment Options

Prescription drug abuse is the use of a
medication not prescribed for you, in a way
other than prescribed (for example, taking
too much), or to get high.

Available treatments depend on the type
of medication being abused.

When abused, prescription drugs can be as
dangerous as “street” drugs, with similar
effects on the brain, including the possibility
of addiction.
Prescription drug abuse is illegal, even
though most abusers get them from friends
and family.
Almost 2.2 million people 12 and older
abused prescription opioids, including pain
relievers, stimulants, and sedatives, for the
first time in 2009 (similar to marijuana).

For Pain Relievers: Addiction treaments
include medications combined with
behavioral therapy.
For Stimulants: Behavioral therapies can be
useful; studies are under way to discover
effective medications.
For Sedatives: Addicted patients should
undergo medically supervised detoxification
combined with behavioral therapy.

Resources
NIDA’s Web site (http://www.drugabuse.gov) has information on all aspects of drug abuse,
such as drug effects on the brain and body, prevention of drug use among young people, latest
research on addiction treatment, and U.S. trends and statistics.
NIDA also has a teen Web site devoted to information about prescription drug abuse:
http://teens.drugabuse.gov/peerx.
The Substance Abuse and Mental Health Services Administration (SAMHSA) has many reports
and bulletins available on prescription drug abuse http://oas.samhsa.gov/prescription.htm.
Their Web site also includes a treatment locator (http://findtreatment.samhsa.gov) and other
useful information.
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15,000

Prescription Painkiller
Overdoses in the US

Nearly 15,000 people die every
year of overdoses involving
prescription painkillers.

1 in 20

In 2010, 1 in 20 people in the
US (age 12 or older) reported
using prescription painkillers
for nonmedical reasons in
the past year.

1 Month

Enough prescription painkillers
were prescribed in 2010 to
medicate every American adult
around-the-clock for a month.

Deaths from prescription painkillers* have
reached epidemic levels in the past decade.
The number of overdose deaths is now greater
than those of deaths from heroin and cocaine
combined. A big part of the problem is
nonmedical use of prescription painkillers—
using drugs without a prescription, or using
drugs just for the “high” they cause. In 2010,
about 12 million Americans (age 12 or older)
reported nonmedical use of prescription
painkillers in the past year.
Enough prescription painkillers were
prescribed in 2010 to medicate every
American adult around-the-clock for a month.
Although most of these pills were prescribed
for a medical purpose, many ended up in the
hands of people who misused or abused them.
Improving the way prescription painkillers are
prescribed can reduce the number of people
who misuse, abuse or overdose from these
powerful drugs, while making sure patients
have access to safe, effective treatment.
* “Prescription painkillers” refers to opioid or narcotic pain
relievers, including drugs such as Vicodin (hydrocodone),
OxyContin (oxycodone), Opana (oxymorphone), and methadone.

See page 4
Want to learn more? Visit
www

National Center for Injury Prevention and Control
Division of Unintentional Injury Prevention

http://www.cdc.gov/vitalsigns
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Overdose deaths from prescription
painkillers have skyrocketed
during
the
past
decade.
Problem
Prescription painkiller overdoses are a
public health epidemic.
◊◊ Prescription painkiller overdoses killed nearly
15,000 people in the US in 2008. This is more
than 3 times the 4,000 people killed by these
drugs in 1999.
◊◊ In 2010, about 12 million Americans (age 12 or
older) reported nonmedical use of prescription
painkillers in the past year.
◊◊ Nearly half a million emergency department
visits in 2009 were due to people misusing or
abusing prescription painkillers.
◊◊ Nonmedical use of prescription painkillers costs
health insurers up to $72.5 billion annually in
direct health care costs.
Certain groups are more likely to abuse or
overdose on prescription painkillers.
◊◊Many more men than women die of overdoses
from prescription painkillers.
◊◊Middle-aged adults have the highest
prescription painkiller overdose rates.
◊◊People in rural counties are about two
times as likely to overdose on prescription
painkillers as people in big cities.
◊◊Whites and American Indian or Alaska
Natives are more likely to overdose on
prescription painkillers.
Real-life stories of the epidemic
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A West Virginia father, age 26, struggling for years with
pain and addiction after shattering his elbow in a car crash,
died from a prescription painkiller one week after telling
his mother he wanted to go to rehab. In New Hampshire,
a 20-year-old man overdosed on a prescription painkiller
bought from a friend, becoming the 9th person that year
to die from drug overdose in his community of 17,000.
Stories such as these are all too common.

◊◊About 1 in 10 American Indian or Alaska
Natives age 12 or older used prescription
painkillers for nonmedical reasons in the past
year, compared to 1 in 20 whites and
1 in 30 blacks.
The supply of prescription painkillers is
larger than ever.
◊◊The quantity of prescription painkillers sold
to pharmacies, hospitals, and doctors’ offices
was 4 times larger in 2010 than in 1999.
◊◊Many states report problems with “pill mills”
where doctors prescribe large quantities
of painkillers to people who don’t need
them medically. Some people also obtain
prescriptions from multiple prescribers by
“doctor shopping.”
Some states have a bigger problem with
prescription painkillers than others.
◊◊Prescription painkiller sales per person were
more than 3 times higher in Florida, which
has the highest rate, than in Illinois, which
has the lowest.
◊◊In 2008/2009, nonmedical use of painkillers
in the past year ranged from 1 in 12 people
(age 12 or older) in Oklahoma to 1 in 30 in
Nebraska.
◊◊States with higher sales per person and
more nonmedical use of prescription
painkillers tend to have more deaths from
drug overdoses.

Rates of prescription painkiller sales, deaths and substance
abuse treatment admissions (1999-2010)
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SOURCES: National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System
(ARCOS) of the Drug Enforcement Administration (DEA), 1999-2010; Treatment Episode Data Set, 1999-2009

Amount of prescription painkillers sold by state per 10,000 people (2010)
WA

AK

MT

ND

ME
MN

OR
ID

VT

SD

HI

WI

WY

MI
PA

UT

IL
CO

CA

AZ

MO

DE

KY

Kilograms of prescription
painkillers per 10,000 people

NC

AR

NM

D.C.

MD

VA

TN

OK

RI

NJ

OH

IN

WV

KS

MA
CT

IA

NE

NV

NH

NY

SC
MS

3.7 - 5.9

GA
AL

6.0 - 7.2

TX
LA

7.3 - 8.4
FL

8.5 - 12.6

SOURCE: Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 2010

Drug overdose death rates by state per 100,000 people (2008)
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What Can Be Done
The US government is

Health insurers can

◊◊Tracking prescription drug overdose trends to
better understand the epidemic.

◊◊Set up prescription claims review programs to
identify and address improper prescribing and
use of painkillers.

◊◊Educating health care providers and the public
about prescription drug abuse and overdose.
◊◊Developing, evaluating and promoting
programs and policies shown to prevent and
treat prescription drug abuse and overdose,
while making sure patients have access to safe,
effective pain treatment.

States can
◊◊Start or improve prescription drug monitoring
programs (PDMPs), which are electronic
databases that track all prescriptions for
painkillers in the state.

Health care providers can
◊◊Follow guidelines for responsible painkiller
prescribing, including
• Screening and monitoring for substance
abuse and mental health problems.
• Prescribing painkillers only when other
treatments have not been effective for pain.

◊◊Use PDMP, Medicaid, and workers’
compensation data to identify improper
prescribing of painkillers.

• Prescribing only the quantity of painkillers
needed based on the expected length
of pain.

◊◊Set up programs for Medicaid, workers’
compensation programs, and state-run health
plans that identify and address improper
patient use of painkillers.

• Using patient-provider agreements
combined with urine drug tests for people
using prescription painkillers long term.

◊◊Pass, enforce and evaluate pill mill, doctor
shopping and other laws to reduce prescription
painkiller abuse.
◊◊Encourage professional licensing boards to
take action against inappropriate prescribing.
◊◊Increase access to substance abuse treatment.

Individuals can
◊◊Use prescription painkillers only as directed by
a health care provider.
◊◊Make sure they are the only one to use their
prescription painkillers. Not selling or sharing
them with others helps prevent misuse and
abuse.
◊◊Store prescription painkillers in a secure place
and dispose of them properly.*
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◊◊Increase coverage for other treatments to
reduce pain, such as physical therapy, and for
substance abuse treatment.

• Talking with patients about safely using,
storing and disposing of prescription
painkillers.*
◊◊Use PDMPs to identify patients who are
improperly using prescription painkillers.
* Information on the proper storage and disposal of medications
can be found at www.cdc.gov/HomeandRecreationalSafety/
Poisoning/preventiontips.htm.

For more information, please contact

Telephone: 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348
E-mail: cdcinfo@cdc.gov
Web: www.cdc.gov
Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333
Publication date: 11/01/2011

www

http://www.cdc.gov/vitalsigns

www

http://www.cdc.gov/mmwr

◊◊Get help for substance abuse problems if
needed (1-800-662-HELP).
CS227796-B

APPENDIX G

Controlled Substances
- by DEA Drug Code Number -

SUBSTANCE

DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

Codeine preparations - 200 mg/(100 ml or 100 gm)

V

Y

Cosanyl,Robitussin A-C,Cheracol,Cerose,Pediacof

Difenoxin preparations - 0.5 mg/25 ug AtSO4/du

V

Y

Motofen

Dihydrocodeine preparations 10 mg/(100 ml or 100 gm)

V

Y

Cophene-S, various others

Diphenoxylate preparations 2.5 mg/25 ug AtSO4

V

Y

Lomotil, Logen

Ethylmorphine preparations 100 mg/(100 ml or 100 gm)

V

Y

Opium preparations - 100 mg/(100 ml or 100 gm)

V

Y

Parepectolin, Kapectolin PG, Kaolin Pectin P.G.

Amphetamine

1100

II

N

Dexedrine, Adderall, Obetrol

Methamphetamine

1105

II

N

Desoxyn, D-desoxyephedrine, ICE, Crank, Speed

Lisdexamfetamine

1205

II

N

Vyvanse

Benzphetamine

1228

III

N

Didrex, Inapetyl

Cathine

1230

IV

N

Constituent of "Khat" plant, (+)-norpseudoephedrine

Cathinone

1235

I

N

Constituent of "Khat" plant

Methcathinone

1237

I

N

N-Methylcathinone, "cat"

4-Methyl-N-methylcathinone

1248

I

N

Mephedrone

Stimulant compounds previously excepted

1405

III

N

Mediatric

N-Ethylamphetamine

1475

I

N

NEA

N,N-Dimethylamphetamine

1480

I

N

Pyrovalerone

1485

V

N

Centroton, Thymergix

Fenethylline

1503

I

N

Captagon,amfetyline,ethyltheophylline amphetamine

Pemoline

1530

IV

N

Cylert

Fenproporex

1575

IV

N

Gacilin, Solvolip

Mefenorex

1580

IV

N

Anorexic, Amexate, Doracil, Pondinil

Aminorex

1585

I

N

has been sold as methamphetamine

4-Methylaminorex (cis isomer)

1590

I

N

U4Euh, McN-422

Mazindol

1605

IV

N

Sanorex, Mazanor

Diethylpropion

1610

IV

N

Tenuate, Tepanil

Phendimetrazine

1615

III

N

Plegine, Prelu-2, Bontril, Melfiat, Statobex

Phenmetrazine

1631

II

N

Preludin

SPA

1635

IV

N

1-dimethylamino-1,2-diphenylethane, Lefetamine

Phentermine

1640

IV

N

Ionamin, Fastin, Adipex-P, Obe-Nix, Zantryl

Chlorphentermine

1645

III

N

Pre-Sate, Lucofen, Apsedon, Desopimon

Clortermine

1647

III

N

Voranil

Dexfenfluramine

1670

IV

N

Redux
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SUBSTANCE

DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

Fenfluramine

1670

IV

N

Pondimin, Ponderal

Sibutramine

1675

IV

N

Meridia

Modafinil

1680

IV

N

Provigil

Methylphenidate

1724

II

N

Concerta, Ritalin, Methylin

Pipradrol

1750

IV

N

Detaril, Stimolag Fortis

Fencamfamin

1760

IV

N

Reactivan

Gamma Hydroxybutyric Acid

2010

I

N

GHB, gamma hydroxybutyrate, sodium oxybate

Gamma Hydroxybutyric Acid preparations

2012

III

N

Xyrem

Embutramide

2020

III

N

Tributane

Aprobarbital

2100

III

N

Alurate

Barbituric acid derivative

2100

III

N

Barbiturates not specifically listed

Butabarbital (secbutabarbital)

2100

III

N

Butisol, Butibel

Butalbital

2100

III

N

Fiorinal, Butalbital with aspirin

Butobarbital (butethal)

2100

III

N

Soneryl (UK)

Talbutal

2100

III

N

Lotusate

Thiamylal

2100

III

N

Surital

Thiopental

2100

III

N

Pentothal

Vinbarbital

2100

III

N

Delvinal, vinbarbitone

Amobarbital

2125

II

N

Amytal, Tuinal

Amobarbital & noncontrolled active ingred.

2126

III

N

Amobarbital suppository dosage form

2126

III

N

Fospropofol

2138

IV

N

Lusedra

Barbital

2145

IV

N

Veronal, Plexonal, barbitone

Methylphenobarbital (mephobarbital)

2250

IV

N

Mebaral, mephobarbital

Methohexital

2264

IV

N

Brevital

Pentobarbital

2270

II

N

Nembutal

Pentobarbital & noncontrolled active ingred.

2271

III

N

FP-3

Pentobarbital suppository dosage form

2271

III

N

WANS

Phenobarbital

2285

IV

N

Luminal, Donnatal, Bellergal-S

Secobarbital

2315

II

N

Seconal, Tuinal

Secobarbital & noncontrolled active ingred

2316

III

N

Secobarbital suppository dosage form

2316

III

N

Chloral betaine

2460

IV

N

Beta Chlor

Chloral hydrate

2465

IV

N

Noctec

Dichloralphenazone

2467

IV

N

Midrin, dichloralantipyrine

Chlorhexadol

2510

III

N

Mechloral, Mecoral, Medodorm, Chloralodol

Ethchlorvynol

2540

IV

N

Placidyl
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SUBSTANCE

DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

Ethinamate

2545

IV

N

Valmid, Valamin

Glutethimide

2550

II

N

Doriden, Dorimide

Methaqualone

2565

I

N

Quaalude, Parest, Somnafac, Opitimil, Mandrax

Mecloqualone

2572

I

N

Nubarene

Methyprylon

2575

III

N

Noludar

Paraldehyde

2585

IV

N

Paral

Petrichloral

2591

IV

N

Pentaerythritol chloral, Periclor

Sulfondiethylmethane

2600

III

N

Sulfonethylmethane

2605

III

N

Sulfonmethane

2610

III

N

Clonazepam

2737

IV

N

Klonopin, Clonopin

Chlordiazepoxide

2744

IV

N

Librium, Libritabs, Limbitrol, SK-Lygen

Lacosamide

2746

V

N

Vimpat

Bromazepam

2748

IV

N

Lexotan, Lexatin, Lexotanil

Camazepam

2749

IV

N

Albego, Limpidon, Paxor

Clobazam

2751

IV

N

Urbadan, Urbanyl

Clotiazepam

2752

IV

N

Trecalmo, Rize, Clozan, Veratran

Cloxazolam

2753

IV

N

Akton, Lubalix, Olcadil, Sepazon

Delorazepam

2754

IV

N

Estazolam

2756

IV

N

Ethyl loflazepate

2758

IV

N

Fludiazepam

2759

IV

N

Halazepam

2762

IV

N

Paxipam

Flunitrazepam

2763

IV

N

Rohypnol, Narcozep, Darkene, Roipnol

Prazepam

2764

IV

N

Centrax

Diazepam

2765

IV

N

Valium, Diastat

Flurazepam

2767

IV

N

Dalmane

Clorazepate

2768

IV

N

Tranxene

Haloxazolam

2771

IV

N

Ketazolam

2772

IV

N

Loprazolam

2773

IV

N

Lormetazepam

2774

IV

N

Noctamid

Zaleplon

2781

IV

N

Sonata

Pregabalin

2782

V

N

Lyrica

Zolpidem

2783

IV

N

Ambien, Ivadal, Stilnoct, Stilnox

Zopiclone

2784

IV

N

Lunesta

Mebutamate

2800

IV

N

Capla

ProSom, Domnamid, Eurodin, Nuctalon

Anxon, Loftran, Solatran, Contamex
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DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

Meprobamate

2820

IV

N

Miltown, Equanil, Micrainin, Equagesic, Meprospan

Nitrazepam

2834

IV

N

Mogadon

Oxazepam

2835

IV

N

Serax, Serenid-D

Medazepam

2836

IV

N

Nobrium

Nimetazepam

2837

IV

N

Erimin

Nordiazepam

2838

IV

N

Nordazepam, Demadar, Madar

Oxazolam

2839

IV

N

Serenal, Convertal

Quazepam

2881

IV

N

Doral

Alprazolam

2882

IV

N

Xanax

Pinazepam

2883

IV

N

Domar

Midazolam

2884

IV

N

Versed

Lorazepam

2885

IV

N

Ativan

Tetrazepam

2886

IV

N

Myolastan, Musaril

Triazolam

2887

IV

N

Halcion

Temazepam

2925

IV

N

Restoril

13Beta-ethyl-17beta-hydroxygon-4-en-3-one

4000

III

N

17Alpha-methyl-3alpha,17beta-dihydroxy-5alphaandrostane

4000

III

N

17Alpha-methyl-3beta,17beta-dihydroxy-5alphaandrostane

4000

III

N

17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene

4000

III

N

17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl4-hydroxy-17beta-hydroxyestr-4-en-3-one)

4000

III

N

17Alpha-methyl-delta1-dihydrotestosterone (17betahydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)

4000

III

N

19-Nor-4,9(10)-androstadienedione

4000

III

N

19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4ene; 3alpha,17beta-dihydroxyestr-4-ene)

4000

III

N

19-Nor-4-androstenedione (estr-4-en-3,17-dione)

4000

III

N

19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5ene; 3alpha,17beta-dihydroxyestr-5-ene)

4000

III

N

19-Nor-5-androstenedione (estr-5-en-3,17-dione)

4000

III

N

1-Androstenediol (3beta,17beta-dihydroxy-5alphaandrost-1-ene; 3alpha,17beta-dihydroxy-5alphaandrost-1-ene)

4000

III

N

1-Androstenedione (5alpha-androst-1-en-3,17-dione)

4000

III

N

3Alpha,17beta-dihydroxy-5alpha-androstane

4000

III

N

3Beta,17beta-dihydroxy-5alpha-androstane

4000

III

N

4-Androstenediol (3beta,17beta-dihydroxy-androst-4ene)

4000

III

N

4-Androstenedione (androst-4-en-3,17-dione)

4000

III

N

4-Dihydrotestosterone (17beta-hydroxyandrostan-3one)

4000

III

N

17-Alpha-methyl-1-testosterone

4-AD

Anabolex, Andractim, Pesomax, Stanolone
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DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr4-en-3-one)

4000

III

N

4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4en-3-one)

4000

III

N

5-Androstenediol (3beta,17beta-dihydroxy-androst-5ene)

4000

III

N

5-Androstenedione (androst-5-en-3,17-dione)

4000

III

N

Anabolic steroids

4000

III

N

Androstanedione (5alpha-androstan-3,17-dione)

4000

III

N

Bolasterone (7alpha,17alpha-dimethyl-17betahydroxyandrost-4-en-3-one)

4000

III

N

Boldenone (17beta-hydroxyandrost-1,4-diene-3-one)

4000

III

N

Boldione

4000

III

N

Calusterone (7beta,17alpha-dimethyl-17betahydroxyandrost-4-en-3-one)

4000

III

N

Methosarb

Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one)

4000

III

N

Alfa-Trofodermin, Clostene, 4-chlorotestosterone

Dehydrochloromethyltestosterone (4-chloro-17betahydroxy-17alpha-methylandrost-1,4-dien-3-one)

4000

III

N

Oral-Turinabol

Delta1-dihydrotestosterone (17beta-hydroxy-5alphaandrost-1-en-3-one)

4000

III

N

1-Testosterone

Desoxymethyltestosterone

4000

III

N

Drostanolone (17beta-hydroxy-2alpha-methyl-5alphaandrostan-3-one)

4000

III

N

Drolban, Masterid, Permastril

Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene)

4000

III

N

Maxibolin, Orabolin, Durabolin-O, Duraboral

Fluoxymesterone (9-fluoro-17alpha-methyl11beta,17beta-dihydroxyandrost-4-en-3-one)

4000

III

N

Anadroid-F, Halotestin, Ora-Testryl

Formebolone (2-formyl-17alpha-methyl11alpha,17beta-dihydroxyandrost-1,4-dien-3-one)

4000

III

N

Esiclene, Hubernol

Furazabol (17alpha-methyl-17betahydroxyandrostano[2,3-c]-furazan)

4000

III

N

Frazalon, Miotolon, Qu Zhi Shu

Mestanolone (17alpha-methyl-17beta-hydroxy-5alphaandrostan-3-one)

4000

III

N

Assimil, Ermalone, Methybol, Tantarone

Mesterolone (1alpha-methyl-17beta-hydroxy-5alphaandrostan-3-one)

4000

III

N

Androviron, Proviron, Testiwop

Methandienone (17alpha-methyl-17betahydroxyandrost-1,4-diene-3-one)

4000

III

N

Dianabol, Metabolina, Nerobol, Perbolin

Methandriol (17alpha-methyl-3beta,17betadihydroxyandrost-5-ene)

4000

III

N

Sinesex, Stenediol, Troformone

Methenolone (1-methyl-17beta-hydroxy-5alpha-androst1-en-3-one)

4000

III

N

Primobolan, Primobolan Depot, Primobolan S

Methyldienolone (17alpha-methyl-17beta-hydroxyestr4,9(10)-dien-3-one)

4000

III

N

Methyltestosterone (17alpha-methyl-17betahydroxyandrost-4-en-3-one)

4000

III

N

Android, Oreton, Testred, Virilon

Methyltrienolone (17alpha-methyl-17beta-hydroxyestr4,9,11-trien-3-one)

4000

III

N

Metribolone

Mibolerone (7alpha,17alpha-dimethyl-17betahydroxyestr-4-en-3-one)

4000

III

N

Cheque, Matenon

Nandrolone (17beta-hydroxyestr-4-en-3-one)

4000

III

N

Deca-Durabolin, Durabolin, Durabolin-50

"Body Building" drugs

Equipoise, Parenabol, Vebonol, dehydrotestosterone
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SUBSTANCE

DEA
NUMBER

CSA
SCH NARC

OTHER NAMES

Norbolethone (13beta,17alpha-diethyl-17betahydroxygon-4-en-3-one)

4000

III

N

Genabol

Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one

4000

III

N

Anabol-4-19, Lentabol

Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4en-3-one)

4000

III

N

Nilevar, Pronabol, Solevar

Normethandrolone (17alpha-methyl-17betahydroxyestr-4-en-3-one)

4000

III

N

Lutenin, Matronal, Orgasteron

Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa5alpha-androstan-3-one)

4000

III

N

Anavar, Lonavar, Oxandrin, Provitar, Vasorome

Oxymesterone (17alpha-methyl-4,17betadihydroxyandrost-4-en-3-one)

4000

III

N

Anamidol, Balnimax, Oranabol, Oranabol 10

Oxymetholone (17alpha-methyl-2-hydroxymethylene17beta-hydroxy-5alpha-androstan-3-one)

4000

III

N

Anadrol-50, Adroyd, Anapolon, Anasteron, Pardroyd

Stanozolol (17alpha-methyl-17beta-hydroxy-5alphaandrost-2-eno[3,2-c]-pyrazole)

4000

III

N

Winstrol, Winstrol-V

Stenbolone (17beta-hydroxy-2-methyl--5alpha-androst1-en-3-one)

4000

III

N

Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta1,4-dien-17-oic acid lactone)

4000

III

N

Teolit, Teslac

Testosterone (17beta-hydroxyandrost-4-en-3-one)

4000

III

N

Android-T, Androlan, Depotest, Delatestryl

Tetrahydrogestrinone (13beta,17alpha-diethyl-17betahydroxygon-4,9,11-trien-3-one)

4000

III

N

THG

Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one)

4000

III

N

Finaplix-S, Finajet, Parabolan

JWH-018 (also known as AM678)

7118

I

N

1-Pentyl-3-(1-naphthoyl)indole

JWH-073

7173

I

N

1-Butyl-3-(1-naphthoyl)indole

JWH-200

7200

I

N

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole

Alpha-ethyltryptamine

7249

I

N

ET, Trip

Ibogaine

7260

I

N

Constituent of "Tabernanthe iboga" plant

Ketamine

7285

III

N

Ketaset, Ketalar, Special K, K

Tiletamine & Zolazepam Combination Product

7295

III

N

Telazol

CP-47497

7297

I

N

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexylphenol

CP-47497 C8 Homologue

7298

I

N

5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexylphenol

Lysergic acid

7300

III

N

LSD precursor

Lysergic acid amide

7310

III

N

LSD precursor

Lysergic acid diethylamide

7315

I

N

LSD, lysergide

2,5-Dimethoxy-4-(n)-propylthiophenethylamine

7348

I

N

2C-T-7

Marihuana

7360

I

N

Cannabis, marijuana

Dronabinol (synthetic) in sesame oil in soft gelatin
capsule as approved by FDA

7369

III

N

Marinol, synthetic THC in sesame oil/soft gelatin as
approved by FDA

Tetrahydrocannabinols

7370

I

N

THC, Delta-8 THC, Delta-9 THC, dronabinol and others

Parahexyl

7374

I

N

Synhexyl,

Nabilone

7379

II

N

Cesamet

Mescaline

7381

I

N

Constituent of "Peyote" cacti
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3,4,5-Trimethoxyamphetamine

7390

I

N

TMA

4-Bromo-2,5-dimethoxyamphetamine

7391

I

N

DOB, 4-bromo-DMA

4-Bromo-2,5-dimethoxyphenethylamine

7392

I

N

2C-B, Nexus, has been sold as Ecstasy, i.e. MDMA

4-Methyl-2,5-dimethoxyamphetamine

7395

I

N

DOM, STP

2,5-Dimethoxyamphetamine

7396

I

N

DMA, 2,5-DMA

2,5-Dimethoxy-4-ethylamphetamine

7399

I

N

DOET

3,4-Methylenedioxyamphetamine

7400

I

N

MDA, Love Drug

5-Methoxy-3,4-methylenedioxyamphetamine

7401

I

N

MMDA

N-Hydroxy-3,4-methylenedioxyamphetamine

7402

I

N

N-hydroxy MDA

3,4-Methylenedioxy-N-ethylamphetamine

7404

I

N

N-ethyl MDA, MDE, MDEA

3,4-Methylenedioxymethamphetamine

7405

I

N

MDMA, Ecstasy, XTC

4-Methoxyamphetamine

7411

I

N

PMA

Peyote

7415

I

N

Cactus which contains mescaline

5-Methoxy-N-N-dimethyltryptamine

7431

I

N

5-MeO-DMT

Alpha-methyltryptamine

7432

I

N

AMT

Bufotenine

7433

I

N

Mappine, N,N-dimethylserotonin

Diethyltryptamine

7434

I

N

DET

Dimethyltryptamine

7435

I

N

DMT

Psilocybin

7437

I

N

Constituent of "Magic mushrooms"

Psilocyn

7438

I

N

Psilocin, constituent of "Magic mushrooms"

5-Methoxy-N,N-diisopropyltryptamine

7439

I

N

5-MeO-DIPT

N-Ethyl-1-phenylcyclohexylamine

7455

I

N

PCE

1-(1-Phenylcyclohexyl)pyrrolidine

7458

I

N

PCPy, PHP, rolicyclidine

1-Phenylcyclohexylamine

7460

II

N

PCP precursor

1-[1-(2-Thienyl)cyclohexyl]piperidine

7470

I

N

TCP, tenocyclidine

Phencyclidine

7471

II

N

PCP, Sernylan

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine

7473

I

N

TCPy

N-Ethyl-3-piperidyl benzilate

7482

I

N

JB 323

N-Methyl-3-piperidyl benzilate

7484

I

N

JB 336

N-Benzylpiperazine

7493

I

N

BZP, 1-benzylpiperazine

3,4-Methylenedioxypyrovalerone

7535

I

N

MDPV

3,4-Methylenedioxy-N-methylcathinone

7540

I

N

Methylone

4-Anilino-N-phenethyl-4-piperidine (ANPP)

8333

II

N

ANPP

Phenylacetone

8501

II

N

P2P, phenyl-2-propanone, benzyl methyl ketone

1-Piperidinocyclohexanecarbonitrile

8603

II

N

PCC, PCP precursor

Alphaprodine

9010

II

Y

Nisentil

Anileridine

9020

II

Y

Leritine
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Coca Leaves

9040

II

Y

Cocaine

9041

II

Y

Methyl benzoylecgonine, Crack

Codeine

9050

II

Y

Morphine methyl ester, methyl morphine

Acetyldihydrocodeine

9051

I

Y

Acetylcodone

Benzylmorphine

9052

I

Y

Codeine-N-oxide

9053

I

Y

Cyprenorphine

9054

I

Y

Desomorphine

9055

I

Y

Etorphine (except HCl)

9056

I

Y

Etorphine HCl

9059

II

Y

M 99

Buprenorphine

9064

III

Y

Buprenex, Temgesic, Subutex, Suboxone

Codeine methylbromide

9070

I

Y

Dihydrocodeine

9120

II

Y

Didrate, Parzone

Oxycodone

9143

II

Y

OxyContin, Percocet, Endocet, Roxicodone, Roxicet,

Dihydromorphine

9145

I

Y

Hydromorphone

9150

II

Y

Dilaudid, dihydromorphinone

Difenoxin 1 mg/25 ug AtSO4/du

9167

IV

Y

Motofen

Difenoxin

9168

I

Y

Lyspafen

Diphenoxylate

9170

II

Y

Benzoylecgonine

9180

II

Y

Cocaine metabolite

Ecgonine

9180

II

Y

Cocaine precursor, in Coca leaves

Ethylmorphine

9190

II

Y

Dionin

Hydrocodone

9193

II

Y

dihydrocodeinone

Heroin

9200

I

Y

Diacetylmorphine, diamorphine

Levomethorphan

9210

II

Y

Levorphanol

9220

II

Y

Levo-Dromoran

Isomethadone

9226

II

Y

Isoamidone

Meperidine

9230

II

Y

Demerol, Mepergan, pethidine

Meperidine intermediate-A

9232

II

Y

Meperidine precursor

Meperidine intermediate-B

9233

II

Y

Meperidine precursor, normeperidine

Meperidine intermediate-C

9234

II

Y

Meperidine precursor

Metazocine

9240

II

Y

Methadone

9250

II

Y

Dolophine, Methadose, Amidone

Methadone intermediate

9254

II

Y

Methadone precursor

Metopon

9260

II

Y

Dextropropoxyphene, bulk (non-dosage forms)

9273

II

Y

Propoxyphene

Dextropropoxyphene dosage forms

9278

IV

Y

Darvon, propoxyphene, Darvocet, Propacet
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Morphine

9300

II

Y

MS Contin, Roxanol, Oramorph, RMS, MSIR

Hydromorphinol

9301

I

Y

Methyldesorphine

9302

I

Y

Methyldihydromorphine

9304

I

Y

Morphine methylbromide

9305

I

Y

Morphine methylsulfonate

9306

I

Y

Morphine-N-oxide

9307

I

Y

Myrophine

9308

I

Y

Nicocodeine

9309

I

Y

Nicomorphine

9312

I

Y

Normorphine

9313

I

Y

Pholcodine

9314

I

Y

Copholco, Adaphol, Codisol, Lantuss, Pholcolin

Thebacon

9315

I

Y

Acetylhydrocodone, Acedicon, Thebacetyl

Acetorphine

9319

I

Y

Oripavine

9330

II

Y

Thebaine

9333

II

Y

Precursor of many narcotics

Dihydroetorphine

9334

II

Y

DHE

Drotebanol

9335

I

Y

Metebanyl, oxymethebanol

Nalorphine

9400

III

Y

Nalline

Opium, raw

9600

II

Y

Raw opium, gum opium

Acetylmethadol

9601

I

Y

Methadyl acetate

Allylprodine

9602

I

Y

Alphacetylmethadol except levo-alphacetylmethadol

9603

I

Y

Alphameprodine

9604

I

Y

Alphamethadol

9605

I

Y

Benzethidine

9606

I

Y

Betacetylmethadol

9607

I

Y

Betameprodine

9608

I

Y

Betamethadol

9609

I

Y

Opium extracts

9610

II

Y

Betaprodine

9611

I

Y

Clonitazene

9612

I

Y

Dextromoramide

9613

I

Y

Diampromide

9615

I

Y

Diethylthiambutene

9616

I

Y

Dimenoxadol

9617

I

Y

Dimepheptanol

9618

I

Y

Vilan

Palfium, Jetrium, Narcolo
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Dimethylthiambutene

9619

I

Y

Opium fluid extract

9620

II

Y

Dioxaphetyl butyrate

9621

I

Y

Dipipanone

9622

I

Y

Ethylmethylthiambutene

9623

I

Y

Etonitazene

9624

I

Y

Etoxeridine

9625

I

Y

Furethidine

9626

I

Y

Hydroxypethidine

9627

I

Y

Ketobemidone

9628

I

Y

OTHER NAMES

Dipipan, phenylpiperone HCl, Diconal, Wellconal

Cliradon

Levomoramide

9629

I

Y

Opium tincture

9630

II

Y

Levophenacylmorphan

9631

I

Y

Morpheridine

9632

I

Y

Noracymethadol

9633

I

Y

Norlevorphanol

9634

I

Y

Normethadone

9635

I

Y

Norpipanone

9636

I

Y

Phenadoxone

9637

I

Y

Phenampromide

9638

I

Y

Opium, powdered

9639

II

Y

Powdered opium

Opium, granulated

9640

II

Y

Granulated opium

Phenoperidine

9641

I

Y

Operidine, Lealgin

Piritramide

9642

I

Y

Piridolan

Proheptazine

9643

I

Y

Properidine

9644

I

Y

Racemoramide

9645

I

Y

Trimeperidine

9646

I

Y

Phenomorphan

9647

I

Y

Levo-alphacetylmethadol

9648

II

Y

LAAM, long acting methadone, levomethadyl acetate

Propiram

9649

I

Y

Algeril

Opium poppy

9650

II

Y

Papaver somniferum

Poppy Straw

9650

II

Y

Opium poppy capsules, poppy heads

Oxymorphone

9652

II

Y

Numorphan

1-Methyl-4-phenyl-4-propionoxypiperidine

9661

I

Y

MPPP, synthetic heroin

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

9663

I

Y

PEPAP, synthetic heroin

Poppy Straw Concentrate

9670

II

Y

Concentrate of Poppy Straw, CPS

Laudanum

Phenyldimazone

Promedolum
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Pentazocine

9709

IV

N

Talwin, Talwin NX, Talacen, Talwin Compound

Phenazocine

9715

II

Y

Narphen, Prinadol

Butorphanol

9720

IV

N

Stadol, Stadol NS, Torbugesic, Torbutrol

Piminodine

9730

II

Y

Racemethorphan

9732

II

Y

Racemorphan

9733

II

Y

Dromoran

Alfentanil

9737

II

Y

Alfenta

Remifentanil

9739

II

Y

Ultiva

Sufentanil

9740

II

Y

Sufenta

Carfentanil

9743

II

Y

Wildnil

Tilidine

9750

I

Y

Tilidate, Valoron, Kitadol, Lak, Tilsa

Tapentadol

9780

II

Y

Bezitramide

9800

II

Y

Burgodin

Fentanyl

9801

II

Y

Duragesic, Oralet, Actiq, Sublimaze, Innovar

Moramide-intermediate

9802

II

Y

Codeine & isoquinoline alkaloid 90 mg/du

9803

III

Y

Codeine with papaverine or noscapine

Codeine combination product 90 mg/du

9804

III

Y

Empirin,Fiorinal,Tylenol,ASA or APAP w/codeine

Hydrocodone & isoquinoline alkaloid <15 mg/du

9805

III

Y

Dihydrocodeinone+papaverine or noscapine

Hydrocodone combination product <15 mg/du

9806

III

Y

Lorcet, Lortab,Vicodin, Vicoprofen,Tussionex, Norco

Dihydrocodeine combination product 90 mg/du

9807

III

Y

Synalgos-DC, Compal

Ethylmorphine combination product 15 mg/du

9808

III

Y

Opium combination product 25 mg/du

9809

III

Y

Morphine combination product/50 mg/(100 ml or 100
gm)

9810

III

Y

Para-Fluorofentanyl

9812

I

Y

China White, fentanyl

3-Methylfentanyl

9813

I

Y

China White, fentanyl

Alpha-methylfentanyl

9814

I

Y

China White, fentanyl

Acetyl-alpha-methylfentanyl

9815

I

Y

Beta-hydroxyfentanyl

9830

I

Y

China White, fentanyl

Beta-hydroxy-3-methylfentanyl

9831

I

Y

China White, fentanyl

Alpha-methylthiofentanyl

9832

I

Y

China White, fentanyl

3-Methylthiofentanyl

9833

I

Y

Chine White, fentanyl

Thiofentanyl

9835

I

Y

Chine white, fentanyl

Paregoric, other combination products
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For more information about the work of the Commission and implementation of
prescription drug abuse prevention strategies, please contact:
Joseph P. Harding, Director
New Hampshire Department of Health & Human Services
Bureau of Drug and Alcohol Services
(603) 271-6110
105 pleasant Street
Concord, NH 03301
Joseph.p.harding@dhhs.state.nh.us

For more information about the development and compilation of this publication,
please contact:
Lisa Muré, Director
New Hampshire Center for Excellence
Community Health Institute/JSI Research & Training Institute
501 South Street, 2nd Floor
Bow, NH 03304

(603) 573-3311
lmure@jsi.com

This document was prepared for The New Hampshire Governor’s Commission on Alcohol and Drug Abuse Prevention,
Intervention and Treatment by the Community Health Institute/JSI under the New Hampshire Center for Excellence
contract funded by the New Hampshire Bureau of Drug and Alcohol Services/Governor's Commission on Alcohol and
Drug Abuse (Contract # 1003181) and the New Hampshire Charitable Foundation.

